JOHNSON & JOHNSON, 10-Q filed on 4/22/2026
Quarterly Report
v3.26.1
Cover - shares
 3 Months Ended
Mar. 29, 2026
Apr. 17, 2026
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 29, 2026  
Document Transition Report false  
Entity File Number 1-3215  
Entity Registrant Name Johnson & Johnson  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1024240  
Entity Address, Address Line One One Johnson & Johnson Plaza  
Entity Address, City or Town New Brunswick  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08933  
City Area Code 732  
Local Phone Number 524-0400  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,407,216,971
Entity Central Index Key 0000200406  
Current Fiscal Year End Date --01-03  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Common Stock, Par Value $1.00    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, Par Value $1.00  
Trading Symbol JNJ  
Security Exchange Name NYSE  
1.150% Notes Due November 2028    
Entity Information [Line Items]    
Title of 12(b) Security 1.150% Notes Due November 2028  
Trading Symbol JNJ28  
Security Exchange Name NYSE  
2.700% Notes Due February 2029    
Entity Information [Line Items]    
Title of 12(b) Security 2.700% Notes Due February 2029  
Trading Symbol JNJ29B  
Security Exchange Name NYSE  
3.20% Notes Due November 2032    
Entity Information [Line Items]    
Title of 12(b) Security 3.200% Notes Due June 2032  
Trading Symbol JNJ32  
Security Exchange Name NYSE  
3.050% Notes Due February 2033    
Entity Information [Line Items]    
Title of 12(b) Security 3.050% Notes Due February 2033  
Trading Symbol JNJ33B  
Security Exchange Name NYSE  
1.650% Notes Due May 2035    
Entity Information [Line Items]    
Title of 12(b) Security 1.650% Notes Due May 2035  
Trading Symbol JNJ35  
Security Exchange Name NYSE  
3.350% Notes Due November 2036    
Entity Information [Line Items]    
Title of 12(b) Security 3.350% Notes Due June 2036  
Trading Symbol JNJ36A  
Security Exchange Name NYSE  
3.350% Notes Due February 2037    
Entity Information [Line Items]    
Title of 12(b) Security 3.350% Notes Due February 2037  
Trading Symbol JNJ37B  
Security Exchange Name NYSE  
3.550% Notes Due November 2044    
Entity Information [Line Items]    
Title of 12(b) Security 3.550% Notes Due June 2044  
Trading Symbol JNJ44  
Security Exchange Name NYSE  
3.600% Notes Due February 2045    
Entity Information [Line Items]    
Title of 12(b) Security 3.600% Notes Due February 2045  
Trading Symbol JNJ45  
Security Exchange Name NYSE  
3.700% Notes Due February 2055    
Entity Information [Line Items]    
Title of 12(b) Security 3.700% Notes Due February 2055  
Trading Symbol JNJ55  
Security Exchange Name NYSE  
v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 28, 2025
Current assets:    
Cash and cash equivalents (Note 4) $ 21,688 $ 19,709
Marketable securities 363 393
Accounts receivable, trade, less allowances $174 (2025, $183) 17,721 17,178
Inventories (Note 2) 14,583 14,191
Prepaid expenses and other 4,818 4,153
Total current assets 59,173 55,624
Property, plant and equipment at cost 54,695 54,364
Less: accumulated depreciation (31,425) (31,195)
Property, plant and equipment, net 23,270 23,169
Intangible assets, net (Note 3) 49,061 50,403
Goodwill (Note 3) 48,558 48,772
Deferred taxes on income (Note 5) 6,727 6,874
Other assets 14,105 14,368
Total assets 200,894 199,210
Current liabilities:    
Loans and notes payable 17,460 8,495
Accounts payable 10,460 11,991
Accrued liabilities 7,399 8,594
Accrued rebates, returns and promotions 18,399 19,124
Accrued compensation and employee related obligations 2,911 4,534
Accrued taxes on income (Note 5) 1,087 1,388
Total current liabilities 57,716 54,126
Long-term debt (Note 4) 37,527 39,438
Deferred taxes on income (Note 5) 7,011 6,791
Employee related obligations (Note 6) 6,760 6,957
Long-term taxes payable (Note 5) 486 486
Other liabilities 10,208 9,868
Total liabilities 119,708 117,666
Commitments and Contingencies (Note 11)
Shareholders’ equity:    
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120
Accumulated other comprehensive income (loss) (Note 7) (14,831) (14,930)
Retained earnings and Additional paid-in capital 169,161 168,978
Less: common stock held in treasury, at cost (713,258,000 and 711,904,000 shares) 76,264 75,624
Total shareholders’ equity 81,186 81,544
Total shareholders’ equity 81,186 81,544
Total liabilities and shareholders’ equity $ 200,894 $ 199,210
v3.26.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 28, 2025
Current assets:    
Allowances for doubtful accounts $ 174 $ 183
Shareholders' equity:    
Common stock, par value per share (in usd per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 4,320,000,000 4,320,000,000
Common stock, shares issued (in shares) 3,119,843,000 3,119,843,000
Treasury stock (in shares) 713,258,000 711,904,000
v3.26.1
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Income Statement [Abstract]    
Sales to customers (Note 9) $ 24,062 $ 21,893
Sales to customers percent to sales 100.00% 100.00%
Cost of products sold $ 8,106 $ 7,357
Cost of products sold percent to sales 33.70% 33.60%
Gross profit $ 15,956 $ 14,536
Gross Profit Percent To Sales 66.30% 66.40%
Selling, marketing and administrative expenses $ 6,034 $ 5,112
Selling marketing and administrative expenses percent to sales 25.10% 23.30%
Research and development expense $ 3,527 $ 3,225
Research and development expense percent to sales 14.70% 14.70%
In-process research and development impairments $ 36 $ 0
In-process research and development percent to sales 0.10% 0.00%
Interest income $ (229) $ (332)
Interest income percent to sales (1.00%) (1.50%)
Interest expense, net of portion capitalized $ 272 $ 204
Interest expense, net of portion capitalized percent to sales 1.20% 0.90%
Other (income) expense, net $ 294 $ (7,321)
Other (income) expense, net percent to sales 1.20% (33.40%)
Restructuring (Note 12) $ 32 $ 17
Restructuring charge percent to sales 0.10% 0.10%
Earnings before provision for taxes on income $ 5,990 $ 13,631
Earnings before provision for taxes on income percent to sales 24.90% 62.30%
Provision for taxes on income (Note 5) $ 755 $ 2,632
Provision for taxes on income percent to sales 3.10% 12.10%
Net earnings from continuing operations percent of sales 21.80% 50.20%
Net earnings $ 5,235 $ 10,999
NET EARNINGS PER SHARE    
Total net earnings per share - basic (in dollars per share) $ 2.17 $ 4.57
Total net earnings per share - diluted (in dollars per share) $ 2.14 $ 4.54
Avg. shares outstanding    
Basic (shares) 2,408.7 2,407.2
Diluted (shares) 2,445.2 2,423.8
v3.26.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Statement of Comprehensive Income [Abstract]    
Net earnings $ 5,235 $ 10,999
Other comprehensive income (loss), net of tax    
Foreign currency translation 334 (575)
Employee benefit plans:    
Prior service cost amortization during period (36) (35)
Gain (loss) amortization during period 75 77
Net change 39 42
Derivatives & hedges:    
Unrealized gain (loss) arising during period (77) 676
Reclassifications to earnings (197) (142)
Net change (274) 534
Other comprehensive income (loss) 99 1
Comprehensive income $ 5,334 $ 11,000
v3.26.1
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Statement of Comprehensive Income [Abstract]    
Foreign currency translation adjustment income (loss) $ (279) $ 400
Employee benefit plans income (loss) 10 11
Derivatives & hedges income (loss) $ (73) $ 142
v3.26.1
Consolidated Statements of Equity - USD ($)
$ in Millions
Total
Retained Earnings and Additional Paid-in Capital
Accumulated Other Comprehensive Income (AOCI)
Common Stock Issued Amount
Treasury Stock Amount
Beginning balance at Dec. 29, 2024 $ 71,490 $ 155,791 $ (11,741) $ 3,120 $ (75,680)
Net earnings 10,999 10,999      
Cash dividends paid (2,989) (2,989)      
Employee compensation and stock option plans 737 (1,166)     1,903
Repurchase of common stock (including excise tax) (2,129)       (2,129)
Other comprehensive income (loss), net of tax 1   1    
Ending balance at Mar. 30, 2025 78,109 162,635 (11,740) 3,120 (75,906)
Beginning balance at Dec. 28, 2025 81,544 168,978 (14,930) 3,120 (75,624)
Net earnings 5,235 5,235      
Cash dividends paid (3,131) (3,131)      
Employee compensation and stock option plans 1,473 (1,921)     3,394
Repurchase of common stock (including excise tax) (4,034)       (4,034)
Other comprehensive income (loss), net of tax 99   99    
Ending balance at Mar. 29, 2026 $ 81,186 $ 169,161 $ (14,831) $ 3,120 $ (76,264)
v3.26.1
Consolidated Statements of Equity (Parenthetical) - $ / shares
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Statement of Stockholders' Equity [Abstract]    
Cash dividends paid (in dollars per share) $ 1.30 $ 1.24
v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Dec. 28, 2025
CASH FLOWS FROM OPERATING ACTIVITIES      
Net earnings $ 5,235 $ 10,999  
Adjustments to reconcile net earnings to cash flows from operating activities:      
Depreciation and amortization of property and intangibles 2,004 1,772  
Stock based compensation 300 288  
Asset write-downs 36 30  
Charges for acquired in-process research and development assets 2 16  
Net loss/(gain) on sale of assets/businesses 12 (75)  
Deferred tax provision 159 2,172  
Credit losses and accounts receivable allowances (8) (4)  
Changes in assets and liabilities, net of effects from acquisitions and divestitures:      
Increase in accounts receivable (595) (926)  
Increase in inventories (431) (146)  
Decrease in accounts payable and accrued liabilities (3,920) (2,126)  
Decrease/(Increase) in other current and non-current assets 349 (1,317)  
Decrease in other current and non-current liabilities (629) (6,509)  
Net cash flows from operating activities 2,514 4,174  
Cash flows used for investing activities      
Additions to property, plant and equipment (1,049) (795)  
Proceeds from the disposal of assets/businesses, net (Note 10) 29 279  
Acquisitions, net of cash acquired (Note 10)     $ (17,500)
Acquired in-process research and development assets / related milestones (Note 10) 0 (14)  
Purchases of investments (144) (251)  
Sales of investments 209 218  
Credit support agreements activity, net (31) 296  
Other (including capitalized licenses and milestones) (54) (30)  
Net cash used for investing activities (1,040) (297)  
Cash flows from financing activities      
Dividends to shareholders (3,131) (2,989)  
Repurchase of common stock (4,028) (2,127)  
Proceeds from short-term debt, net 12,439 8,784  
Repayment of short-term debt, net (3,223) (2,120)  
Proceeds from long-term debt, net of issuance costs 0 9,138  
Repayment of long-term debt (2,002) (751)  
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 1,172 450  
Credit support agreements activity, net (109) (3)  
Other (588) 40  
Net cash from financing activities 530 10,422  
Effect of exchange rate changes on cash and cash equivalents (25) 70  
Increase in cash and cash equivalents 1,979 14,369  
Cash and cash equivalents, beginning of period 19,709 24,105 24,105
Cash and cash equivalents, end of period $ 21,688 $ 38,474 $ 19,709
v3.26.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 29, 2026
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2025. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.
Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
Recently Adopted Accounting Standards
ASU 2025-07: Derivates and Hedging (Topic 815) and Revenue from Contracts with Customers (TOPIC 606)
Effective beginning fiscal year 2026, the Company prospectively adopted the amended guidance issued by the FASB that adds a scope exception to exclude from derivative accounting non-exchange-traded contracts with variables (underlyings) that are based on operations or activities specific to one of the parties to the contract. The adoption of this new accounting standard did not have a material impact on the Company’s consolidated financial statements.
Recently Issued Accounting Standards Not Yet Adopted
There were no new material accounting standards issued in the fiscal first quarter of 2026.
Supplier finance program obligations
The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide enrolled suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to join in the program.
Confirmed obligations under the program as of March 29, 2026, and December 28, 2025, were $0.7 billion and $0.8 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.
v3.26.1
Inventories
 3 Months Ended
Mar. 29, 2026
Inventory Disclosure [Abstract]  
Inventories Inventories
(Dollars in Millions)March 29, 2026December 28, 2025
Raw materials and supplies$2,6122,530
Goods in process4,0333,828
Finished goods7,9387,833
Total inventories$14,58314,191
v3.26.1
Intangible assets and goodwill
 3 Months Ended
Mar. 29, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill Intangible assets and goodwill
Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2025. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.
(Dollars in Millions)March 29, 2026December 28, 2025
Intangible assets with definite lives:  
Patents and trademarks — gross$58,51559,156
Less accumulated amortization
(32,939)
(32,507)
Patents and trademarks — net
$25,576
26,649
Customer relationships and other intangibles — gross21,34021,361
Less accumulated amortization(15,156)(14,998)
Customer relationships and other intangibles — net(1)
$6,184
6,363
Intangible assets with indefinite lives:  
Trademarks1,7661,772
Purchased in-process research and development15,53515,619
Total intangible assets — net$49,06150,403
(1)The majority is comprised of customer relationships
Goodwill as of March 29, 2026 was allocated by segment of business as follows:
(Dollars in Millions)
Innovative
Medicine
MedTechTotal
Goodwill at December 28, 2025
$14,96733,80548,772
Goodwill, related to acquisitions———
Goodwill, related to divestitures———
Currency translation/Other
(155)
(59)
(214)
Goodwill at March 29, 2026
$14,81233,74648,558
    
The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $1.2 billion and $1.1 billion for the fiscal first quarters ended March 29, 2026 and March 30, 2025, respectively.
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20262027202820292030
$5,1004,4003,7003,6003,500
See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.
v3.26.1
Fair value measurements
 3 Months Ended
Mar. 29, 2026
Fair Value Disclosures [Abstract]  
Fair value measurements Fair value measurements
The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.
Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.
The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 29, 2026, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $4.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 29, 2026, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $43.9 billion, $37.9 billion and $8.0 billion, respectively. As of December 28, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $40.6 billion, $38.9 billion and $8.0 billion, respectively.
All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.
Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.
The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.
As of March 29, 2026, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $0.6 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended March 29, 2026 and March 30, 2025, net of tax:


March 29, 2026March 30, 2025
(Dollars in Millions)Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
    Hedged items$———36————188—
    Derivatives designated as hedging instruments———(36)————(188)—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———47————49—
   Amount of gain or (loss) recognized in AOCI———47————49—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income 173(5)—(2)(1)101——
   Amount of gain or (loss) recognized in AOCI (7)(195)37—253105(36)—(11)
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———83————83—
   Amount of gain or (loss) recognized in AOCI$———16————566—
As of March 29, 2026, and December 28, 2025, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is includedCarrying Amount of the Hedged Liability
Cumulative Amount of Fair Value
Hedging Gain/ (Loss) Included in the
Carrying Amount of the Hedged Liability
(Dollars in Millions)March 29, 2026December 28, 2025March 29, 2026December 28, 2025
Long-term Debt$7,3608,318(647)(694)

The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2026 and 2025:
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)Location of
Gain /(Loss)
Recognized in
Income on Derivative		Fiscal First Quarter Ended
Derivatives Not Designated as Hedging InstrumentsMarch 29, 2026March 30, 2025
Foreign Exchange ContractsOther (income) expense$(65)62

The following table is the effect of net investment hedges for the fiscal first quarters ended in 2026 and 2025:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)March 29, 2026March 30, 2025March 29, 2026March 30, 2025
Debt
$213
(316)
Interest (income) expense
—
—
Cross Currency interest rate swaps
$217
840
Interest (income) expense
—
—


The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
The following table is a summary of the activity related to equity investments:
December 28, 2025March 29, 2026
(Dollars in Millions)Carrying Value
Changes in Fair Value Reflected in Net Income (1)
(Sales)/ Purchases/Other (2)
Carrying ValueNon Current Other Assets
Equity Investments with readily determinable value$66543(5)703703
Equity Investments without readily determinable value$91046(68)888888
(1)Recorded in Other (income)/expense, net
(2)Other includes impact of currency

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.
The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.
The following three levels of inputs are used to measure fair value:
Level 1 — Quoted prices in active markets for identical assets and liabilities.
Level 2 — Significant other observable inputs.
Level 3 — Significant unobservable inputs.
The Company’s significant financial assets and liabilities measured at fair value as of March 29, 2026 and December 28, 2025 were as follows:
 March 29, 2026December 28, 2025
(Dollars in Millions)Level 1Level 2Level 3Total
Total(1)
Derivatives designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $—549—549686
Interest rate contracts(2)
—610—610589
Total —1,159—1,1591,275
Liabilities:     
Forward foreign exchange contracts —418—418413
Interest rate contracts(2)
—5,386—5,3865,848
Total —5,804—5,8046,261
Derivatives not designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts —47—4738
Liabilities:     
Forward foreign exchange contracts —49—4946
Other Investments:
Equity investments(3)
703——703665
Debt securities(4)
—6,675—6,6752,854
Other Liabilities:
Contingent consideration(5)
$——754754753
Gross to Net Derivative ReconciliationMarch 29, 2026December 28, 2025
(Dollars in Millions)
Total Gross Assets$1,2061,313
Credit Support Agreement (CSA)(1,094)(1,308)
Total Net Asset1125
Total Gross Liabilities5,8536,307
Credit Support Agreement (CSA)(5,829)(5,903)
Total Net Liabilities$24404
Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended March 29, 2026 and March 30, 2025 is as follows:
March 29, 2026March 30, 2025
(Dollars in Millions)
Beginning Balance$7531,217
Changes in estimated fair value(6)
114
Additions——
Payments——
Ending Balance$7541,231
(1)2025 assets and liabilities are all classified as Level 2 with the exception of equity investments of $665 million, which are classified as Level 1 and contingent consideration of $753 million, classified as Level 3.
(2)Includes cross currency interest rate swaps and interest rate swaps.
(3)Classified as non-current other assets.
(4)Classified within cash equivalents and current marketable securities.
(5)Classified as non-current other liabilities.
(6)Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
As of March 29, 2026 and December 28, 2025, cash and cash equivalents includes money market funds of $5,089 million and $5,993 million, respectively, which would be considered level 1 in the fair value hierarchy

The Company's cash, cash equivalents and current marketable securities as of March 29, 2026 comprised:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash
$3,310
3,310
3,310
—
U.S. reverse repurchase agreements
6,253
6,253
6,253
—
Money market funds
5,089
5,089
5,089
—
Time deposits(1)
724
724
724
—
   Subtotal
15,376
15,376
15,376
—
​
U.S. Gov’t securities
6,225
6,225
6,207
18
Other sovereign securities
234
234
76
158
Corporate and other debt securities
216
216
29
187
   Subtotal available for sale debt(2)
$6,675
6,675
6,312
363
Total cash, cash equivalents and current marketable securities
$22,051
22,051
21,688
363
(1)Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
As of the fiscal year ended December 28, 2025, the carrying amount of cash, cash equivalents and current marketable securities was the same as the estimated fair value.
Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
The contractual maturities of the available for sale securities as of March 29, 2026 are as follows:
(Dollars in Millions)Cost BasisFair Value
Due within one year
$6,659
6,659
Due after one year through five years
16
16
Due after five years through ten years
—
—
Total debt securities
$6,675
6,675
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 29, 2026:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Financial Liabilities  
Current Debt$17,460
17,455
Non-Current Debt  
0.95% Notes due 2027
1,4991,439
2.90% Notes due 2028
1,4991,470
1.150% Notes due 2028 (750MM Euro 1.1541)
863826
4.55% Notes due 2028
749758
4.80% Notes due 2029
1,1471,174
6.95% Notes due 2029
299327
2.70% Notes due 2029 (600MM Euro 1.1541)
692685
1.30% Notes due 2030
1,7021,544
4.70% Notes due 2030
9961,018
4.90% Notes due 2031
1,1461,180
3.20% Notes due 2032 (700MM Euro 1.1541)
805798
4.85% Notes due 2032
1,2431,275
4.95% Notes due 2033
499518
4.375% Notes due 2033
853845
3.050% Notes due 2033 (700MM Euro 1.1541)
806786
4.95% Notes due 2034

847882
1.650% Notes due 2035 (1.5B Euro 1.1541)
1,7221,463
5.00% Notes due 2035
1,2441,275
3.35% Notes due 2036 (800MM Euro 1.1541)

919892
3.587% Notes due 2036
925903
5.95% Notes due 2037
9951,085
3.625% Notes due 2037
1,4141,333
3.350% Notes due 2037 (1.0B Euro 1.1541)
1,1511,100
3.40% Notes due 2038
994855
5.85% Notes due 2038
697754
4.50% Notes due 2040
542512
2.10% Notes due 2040
902687
4.85% Notes due 2041
298292
4.50% Notes due 2043
497453
3.55% Notes due 2044 (1.0B Euro 1.1541)
1,1441,057
3.60% Notes due 2045 (700MM Euro 1.1541)
802741
3.73% Notes due 2046
1,9801,565
3.75% Notes due 2047
877778
3.50% Notes due 2048
744555
2.25% Notes due 2050
864572
5.25% Notes due 2054

843831
3.70% Notes due 2055 (1.0B Euro 1.1541)
1,1481,027
2.45% Notes due 2060
1,118660
Other6277
Total Non-Current Debt$37,52734,992
The weighted average effective interest rate on non-current debt is 3.56%.
The excess of the carrying value over the estimated fair value of debt was $1.7 billion at December 28, 2025.
Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.
The current debt balance as of March 29, 2026, includes $15.7 billion of commercial paper which has a weighted average interest rate of 3.67% and a weighted average maturity of approximately two months. The current debt balance as of December 28, 2025 included $6.5 billion of commercial paper which has a weighted average interest rate of 3.81% and a weighted average maturity of approximately two months.
v3.26.1
Income taxes
 3 Months Ended
Mar. 29, 2026
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The worldwide effective income tax rates for the fiscal first quarter of 2026 and 2025 were 12.6% and 19.3%, respectively. The primary drivers for year over year change in the Company’s effective tax were:
•In the fiscal first quarter of 2025, the Company reversed approximately $7.0 billion related to the talc reserve which was recorded at approximately 22%.
•Additional tax benefits in the fiscal first quarter of 2026 related to the Company’s share-based equity compensation programs that either vested or were exercised during the fiscal first quarters of 2026 and 2025, which reduced the effective tax rate by 5.1% and 0.4%, respectively.
As of March 29, 2026, the Company had approximately $2.6 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in several jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and the audit for tax years 2017 through 2020 is ongoing. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2014.
v3.26.1
Pensions and other benefit plans
 3 Months Ended
Mar. 29, 2026
Retirement Benefits [Abstract]  
Pensions and other benefit plans Pensions and other benefit plans
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal First Quarter Ended
 Retirement PlansOther Benefit Plans
(Dollars in Millions)March 29, 2026March 30, 2025March 29, 2026March 30, 2025
Service cost$2362148072
Interest cost3603515254
Expected return on plan assets(639)(587)(2)(2)
Amortization of prior service cost/(credit)
(46)(46)——
Recognized actuarial (gains)/losses
69
83
26
16
Net periodic benefit cost/(credit)$(20)15156140
The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.
Company contributions
For the fiscal three months ended March 29, 2026, the Company contributed $35 million and $5 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.
v3.26.1
Accumulated other comprehensive income
 3 Months Ended
Mar. 29, 2026
Equity [Abstract]  
Accumulated other comprehensive income Accumulated other comprehensive income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions)
Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit
Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income/(Loss)
December 28, 2025$(13,947)—(693)(290)(14,930)
Net change334—39(274)99
March 29, 2026(13,613)—(654)(564)(14,831)
Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.
Details on reclassifications out of Accumulated Other Comprehensive Income:
Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.
Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.
v3.26.1
Earnings per share
 3 Months Ended
Mar. 29, 2026
Earnings Per Share [Abstract]  
Earnings per share Earnings per share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
 Fiscal First Quarter Ended
(Shares in Millions)March 29, 2026March 30, 2025
Basic net earnings per share$2.174.57
Average shares outstanding — basic2,408.72,407.2
Potential shares exercisable under stock option plans100.669.0
Less: shares which could be repurchased under treasury stock method(64.1)(52.4)
Average shares outstanding — diluted2,445.22,423.8
Diluted net earnings per share$2.144.54
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock.
3.560.9
v3.26.1
Segments of business and geographic areas
 3 Months Ended
Mar. 29, 2026
Segment Reporting [Abstract]  
Segments of business and geographic areas Segments of business and geographic areas
The Company is organized into two business segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
Sales by segment of business
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,6153,01320.0 %
International
3,3582,66426.0 
Worldwide
6,9735,67822.8 
DARZALEX
U.S.
2,2081,82920.7 
International
1,7561,40924.7 
Worldwide
3,9643,23722.5 
CARVYKTI
U.S.
43331836.2
International
16451*
Worldwide
59736962.1
TECVAYLI
U.S.
12710520.6 
International
744663.1
Worldwide
20215133.5 
TALVEY
U.S.
1016848.5 
International
5118*
Worldwide
1528676.7 
RYBREVANT/ LAZCLUZE
U.S.
17511355.1
International
8228*
Worldwide
25714182.7
ERLEADA
U.S.
34229217.3 
International
60747926.7 
Worldwide
94977123.1 
IMBRUVICA
U.S.
143235(39.1)
International
5174749.1 
Worldwide
660709(6.9)
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER ONCOLOGY(1)
U.S.
855458.8 
International
106160(33.9)
Worldwide
192214(10.6)
Immunology
U.S.
1,8552,196(15.5)
International
1,5241,5100.9 
Worldwide
3,3803,707(8.8)
TREMFYA
U.S.
1,04259973.9 
International
56635658.9 
Worldwide
1,60895668.3 
SIMPONI / SIMPONI ARIA
U.S.
269292(7.8)
International
3783663.0 
Worldwide
647659(1.7)
REMICADE
U.S.
269314(14.4)
U.S. Exports
181078.6 
International
136143(4.8)
Worldwide
422467(9.5)
STELARA
U.S.
220981(77.6)
International
435644(32.4)
Worldwide
6561,625(59.7)
OTHER IMMUNOLOGY
U.S.
381*
International
90*
Worldwide
461*
Neuroscience
U.S.
1,49496854.3 
International
6816790.3 
Worldwide
2,1751,64732.0 
SPRAVATO
U.S.
40627647.0 
International
614342.4 
Worldwide
46832046.4 
CAPLYTA(2)
U.S.
270—*
International
——— 
Worldwide
270—*
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
75862521.2 
International
2802771.1 
Worldwide
1,03890315.0 
CONCERTA / methylphenidate
U.S.
2238(43.4)
International
1151104.3 
Worldwide
136148(8.0)
OTHER NEUROSCIENCE
U.S.
382832.6 
International
224248(9.7)
Worldwide
262277(5.4)
Pulmonary Hypertension (PH)
U.S.
83174411.7 
International
3042818.2 
Worldwide
1,1351,02510.7 
UPTRAVI
U.S.3853655.4 
International988614.3 
Worldwide4834517.1 
OPSUMIT/OPSYNVI
U.S.43336319.3 
International1721598.7 
Worldwide60652216.1 
OTHER PULMONARY HYPERTENSION
U.S.
1215(21.1)
International3437(8.3)
Worldwide 4652(12.1)
Infectious Diseases (ID)
U.S.
3423158.6 
International
54748712.2 
Worldwide
88980210.8 
EDURANT / rilpivirine
U.S.
78(13.1)
International
40235014.8 
Worldwide
40935814.1 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
3343059.5 
International
1099811.2 
Worldwide
44340310.0 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER INFECTIOUS DISEASES
U.S.
12(56.9)
International
3639(8.3)
Worldwide
3741(10.4)
Cardiovascular / Metabolism / Other (CVM)
U.S.734855(14.2)
International142158(10.4)
Worldwide8761,013(13.6)
XARELTO
U.S.642690(7.0)
International——— 
Worldwide642690(7.0)
OTHER
U.S.91165(44.5)
International142158(10.4)
Worldwide233323(27.8)
Total PH, ID, CVM
U.S.1,9071,914(0.4)
International9939267.1 
Worldwide2,8992,8402.1 
TOTAL INNOVATIVE MEDICINE
 
 
U.S.8,8718,0929.6 
International6,5555,78113.4 
Worldwide15,42613,87311.2 
MEDTECH
Cardiovascular
U.S.1,3991,26110.9 
International97884216.1 
Worldwide2,3772,10313.0 
ELECTROPHYSIOLOGY
U.S.7366847.6 
International75363818.0 
Worldwide1,4891,32312.6 
ABIOMED
U.S.38933914.5 
International1008123.5 
Worldwide48842016.3 
SHOCKWAVE
U.S.24220617.8 
International635221.3 
Worldwide30525818.5 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER CARDIOVASCULAR
U.S.32320.7 
International6272(13.4)
Worldwide94103(9.1)
Surgery
U.S.
1,046
1,002
4.4 
International
1,465
1,394
5.1 
Worldwide
2,511
2,396
4.8 
ADVANCED
U.S.4774574.2 
International6466164.9 
Worldwide1,1231,0734.6 
GENERAL
U.S.5695444.5 
International8197785.2 
Worldwide1,3881,3234.9 
Vision
U.S.5795662.4 
International78571310.1 
Worldwide1,3651,2796.7 
CONTACT LENSES / OTHER
U.S.4684523.7 
International5014677.2 
Worldwide9699195.5 
SURGICAL
U.S.111114(2.9)
International28524615.6 
Worldwide3963619.7 
Orthopaedics*
U.S.
1,435
1,384
3.7 
International
948
857
10.6 
Worldwide
2,383
2,241
6.3 
HIPS
U.S.
277
263
5.2 
International
159
146
8.9 
Worldwide
436
409
6.5 
KNEES
U.S.
239
231
3.3 
International
181
158
14.6 
Worldwide
420
389
7.9 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
TRAUMA
U.S.
532
502
6.1 
International
301
270
11.4 
Worldwide
833
772
8.0 
SPINE, SPORTS & OTHER
U.S.
387
388
(0.1)
International
307
283
8.4 
Worldwide
694
671
3.5 
TOTAL MEDTECH  
U.S.4,4594,2135.9 
International4,1773,8079.7 
Worldwide8,6368,0207.7 
WORLDWIDE   
U.S.13,33012,3058.3 
International10,7329,58811.9 
Worldwide$24,06221,8939.9%
*    Percentage greater than 100% or not meaningful
(1) Includes the sales of ZYTIGA which were previously disclosed separately
(2) Acquired with Intra-Cellular Therapies on April 2, 2025

Adjustments to revenue recognized as a result of changes in estimates for the Company's most significant U.S. rebates and discounts liability balances for products shipped in previous periods were approximately 4.7% and 4.6% of U.S. Innovative Medicine revenue during the fiscal first quarter of 2026 and 2025, respectively.
*In October 2025, the Company announced its intention to separate its Orthopaedics business. The Company continues to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement.
Segment income before tax
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$15,4268,63613,8738,020
Cost of products sold4,3903,7014,0203,326
Selling, marketing and administrative2,9182,9062,2612,656
Research and development expense2,8137142,548677
Other segment items (3)
(12)76(166)(60)
Segment income before tax$5,3171,2396,5565,2101,4216,631
(Income)/Expense not allocated to segments (4)
566(7,000)
Earnings before provision for taxes on income$5,990$13,631
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.8 billion and $0.6 billion in the fiscal first quarters of 2026 and 2025, respectively.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion in both the fiscal first quarters of 2026 and 2025.
•Orthopaedics Separation related charge of $0.1 billion in the fiscal first quarter of 2026.
•Acquisition and integration related expense of $0.1 billion in the fiscal first quarter of 2025, primarily related to Shockwave.
(3)    Other segment items for each reportable segment include other income and expense (gains and losses on divestitures and gains and losses on sale of assets), restructuring activities and impairment charges related to in-process research and development
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2026 includes charges for talc matters of $0.3 billion. The fiscal first quarter of 2025 includes approximately $7.0 billion related to the talc reserve reversal.
Identifiable Assets
(Dollars in Millions)March 29, 2026December 28, 2025
Innovative Medicine$78,118
78,057
MedTech86,17986,482
Total
164,297
164,539
General corporate (1)
36,59734,671
Worldwide total$200,894199,210
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
Fiscal Three Months Ended
(Dollars in Millions)March 29, 2026March 30, 2025March 29, 2026March 30, 2025
Innovative Medicine$508276$1,036884
MedTech509480903836
Segments total1,0177561,9391,720
General corporate32396552
Worldwide total$1,049795$2,0041,772
Sales by geographic area
 Fiscal First Quarter Ended
(Dollars in Millions)March 29, 2026March 30, 2025Percent
Change
United States$13,33012,3058.3%
Europe5,8485,11014.5 
Western Hemisphere, excluding U.S.1,2931,16710.8 
Asia-Pacific, Africa3,5913,3118.5 
Total$24,06221,8939.9%
v3.26.1
Acquisitions, divestitures and other arrangements
 3 Months Ended
Mar. 29, 2026
Business Combination [Abstract]  
Acquisitions, divestitures and other arrangements Acquisitions, divestitures and other arrangements
Business combinations
Acquisitions of a business are accounted for as business combinations applying the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company’s consolidated financial statements. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. The results of operations of these acquisitions have been included in the Company’s financial statements from their respective dates of acquisition.

In the fiscal first quarter of 2026, there were no material business combinations.
2025 Transactions
During the fiscal year 2025, the Company acquired Halda Therapeutics OpCo, Inc. (Halda Therapeutics) and Intra-Cellular Therapies, Inc. (Intra-Cellular) for a total of $17.5 billion, net of cash acquired.

Halda Therapeutics

On December 26, 2025, the Company completed the acquisition of Halda Therapeutics, a clinical-stage biotechnology company with proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeting therapies for multiple types of solid tumors, including prostate cancer, in an all-cash merger transaction for total consideration transferred of approximately $3.05 billion, net of cash acquired. The acquisition was accounted for as a business combination and the results of operations and goodwill are included in the Innovative Medicine segment as of the acquisition date. Included in the total consideration transferred was $0.2 billion of acquisition-related costs, primarily related to post-closing compensation expense due to the acceleration of equity awards. This expense was recorded in Other (income) expense, net. Acquisition related costs before tax for the fiscal first quarter of 2026 were not material.

The fair value of the assets acquired is $3.4 billion, which primarily relates to acquired in-process research and development (IPR&D) of $2.8 billion and goodwill of $0.6 billion. The fair value of the liabilities assumed is $0.6 billion, primarily related to deferred taxes. These values are preliminary and based on the best estimate of management, which is subject to change within the measurement period. As of the fiscal first quarter ended March 29, 2026, there have been no material measurement period adjustments.

Intra-Cellular
On April 2, 2025, the Company completed the acquisition of Intra-Cellular, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. This acquisition advances the Company’s industry-leading portfolio in mental health with the addition of CAPLYTA (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy and is also approved for the treatment of schizophrenia in adults. This acquisition also includes a promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation.

The Company acquired all the outstanding shares of Intra-Cellular’s common stock for $132.00 per share in an all-cash merger transaction for total consideration transferred of $14.5 billion. The acquisition was accounted for as a business combination and the results of operations and goodwill are included in the Innovative Medicine segment as of the acquisition date. In addition, acquisition-related costs before tax incurred during the fiscal year 2025 were $0.4 billion, of which $0.1 billion related to post-closing compensation expense due to the acceleration of equity awards and were recorded to Other (income) expense, net. Acquisition related costs before tax for the fiscal first quarter of 2026 were not material.
The fair value of the assets acquired is $17.5 billion, which primarily relates to acquired in-process research and development (IPR&D) of $8.3 billion, an amortizable intangible asset of $5.2 billion, goodwill of $2.9 billion and other current and non-current assets of $1.1 billion. The fair value of the liabilities assumed is $3.0 billion, primarily related to deferred taxes. As of the fiscal first quarter ended March 29, 2026, there have been no material measurement period adjustments. During the fiscal fourth quarter of 2025, the U.S. FDA approved CAPLYTA as an adjunctive therapy with anti-depressants for the treatment of major depressive disorder in adults. This IPR&D asset was reclassified to a definite lived asset and began amortizing in the fiscal fourth quarter of 2025.


Asset acquisitions
If it is determined that the acquired set does not meet the definition of a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition. In this case, no goodwill is recorded, acquired in-process research and development (IPR&D) with no alternative future use is immediately recorded as research and development expense and contingent consideration is recorded when the related event occurs.

In the fiscal first quarters of 2026 and 2025, there were no material asset acquisitions.

Divestitures
In the fiscal first quarters of 2026 and 2025, there were no material divestitures.

Other arrangements

In the fiscal first quarter of 2026, the Company entered into a co-funding agreement with Royalty Pharma plc. (Royalty Pharma) under which the Company will receive up to a total of $0.5 billion during the fiscal years 2026 and 2027 to support the clinical development of JNJ-4804, a co-antibody therapy in development to treat chronic immune-mediated diseases. As there is a substantive and genuine transfer of risk to Royalty Pharma, the development funding will be recognized as an obligation to perform contractual services. Accordingly, the funding the Company receives will be recognized as a reduction to research & development expense as the Company performs its contractual services.
If successful, upon regulatory approval of certain indications in the U.S. or other major markets, Royalty Pharma will receive approval-based fixed milestone payments up to approximately $0.5 billion and will also be eligible to receive sales-based milestone payments and low-single digit royalties based on commercial sales.
v3.26.1
Legal proceedings
 3 Months Ended
Mar. 29, 2026
Commitments and Contingencies Disclosure [Abstract]  
Legal proceedings Legal proceedings
Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 29, 2026, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these
matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.
Matters concerning talc
As of March 29, 2026, there are approximately 75,000 plaintiffs in the United States with direct claims against the Company and its affiliates in pending lawsuits regarding injuries allegedly due to use of body powders containing talc, primarily JOHNSON’S Baby Powder.

In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. The Company continues to believe that it has strong legal grounds to contest all the talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases.
In an effort to expeditiously resolve the litigation for the overwhelming majority of claimants, beginning in October 2021, the Company underwent a series of corporate restructurings which ultimately resulted in two entities, Red River Talc, LLC (Red River) and Pecos River Talc LLC (Pecos River), being assigned all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act. As a result of the restructurings, all claims in North America related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims in North America were allocated to Pecos River. In connection with these restructurings, the Company filed a series of three Chapter 11 bankruptcy proceedings. Ultimately, each of the bankruptcy proceedings was dismissed and, as a result, the Company reversed substantially all, or approximately $7.0 billion, from amounts previously reserved for the bankruptcy resolution in the fiscal first quarter of 2025. Litigation in the tort system recommenced.
As of the first quarter of 2026, the total present value of the reserve for talc related matters is approximately $3.4 billion, comprising previously executed settlement agreements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.
As in years prior, both ovarian cancer and mesothelioma trials are being scheduled in various state courts throughout 2026 and beyond. In the ovarian cancer multi-district litigation in New Jersey, the court is addressing the Company's Daubert motions related to general causation, specific causation, and certain asbestos testing methods. In January 2026, the Special Master issued her Report and Recommendation related to general causation, excluding certain opinions by plaintiff experts, but also allowing other opinions to proceed. The Company has filed an appeal of the Report and Recommendation to the District Court. The remaining Daubert motions are expected to be decided in 2026. The Company also faces litigation in Canada.
In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the court denied, in part, the motion to dismiss. In December 2023, the court granted plaintiffs’ motion for class certification. In July 2025, the Third Circuit affirmed the court's order granting class certification. In September 2025, the Company petitioned the Third Circuit for rehearing or rehearing en banc, which was denied in October 2025. In February 2026, the Company filed a writ of certiorari with the United States Supreme Court regarding the Third Circuit’s decision, which the Supreme Court denied in April 2026.
In February 2019, the Company’s talc supplier, Imerys Talc America, Inc., and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys), filed voluntary petitions for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware. In February 2021, Cyprus Mines Corporation (Cyprus), which sold certain talc mines and assets to Imerys, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court. In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases, entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties' ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies regarding (i) the Company's alleged obligations to indemnify Imerys and Cyprus for personal injury claims allegedly caused by exposure to talc contained in the Company's products and (ii) entitlements to proceeds of certain of the Company's insurance policies. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). Certain insurers have appealed the Settlement Order and sought a stay of the Settlement Order pending appeal, which the Delaware Bankruptcy Court denied in January 2025. In August 2025, the District Court denied the insurers' appeal of the Settlement Order. The insurers have appealed that decision to the Third Circuit.
Intellectual property
Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company’s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.

The Company’s Innovative Medicine subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book). In each of these lawsuits, the Company’s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company’s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company’s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.

The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.
Innovative Medicine
XARELTO
Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG, and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy’s Laboratories, Inc.; Dr. Reddy’s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; and Prinston Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In December 2025 and January 2026, the cases against Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; and Prinston Pharmaceuticals, Inc. were dismissed with prejudice. In January 2026, the Company entered into a confidential settlement agreement with Mankind Pharma Limited.

U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. In September 2025, the Federal Circuit entered a decision affirming-in-part, vacating-in-part, and remanding for further proceedings. In January 2026, the USPTO entered judgment against petitioners upon remand.
INVEGA SUSTENNA
Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Eugia Pharma Specialties Ltd.; Eugia US, LLC; and Aurobindo Pharma USA, Inc. The following U.S. patent is included in one or more cases: 9,439,906. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement of a subset of the claims, and based on a claim construction ruling, the district court entered a non-infringement order with respect to the remaining asserted claims. Tolmar has appealed the validity decision, and Janssen appealed the non-infringement decision. In March 2026, Janssen and Tolmar entered into a confidential settlement agreement.

Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entity is a named defendant: Pharmascience Inc. The following Canadian patent is included in one or more cases: 2,655,335. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.
ERLEADA
Beginning in January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc. (collectively, Janssen Inc.), and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz’s filing of ANDSs seeking approval to market 60 mg and 240 mg generic versions of ERLEADA before the expiration of CA Patent Nos. 3,008,345, 2,875,767, 2,885,415, and 3,128,331. Janssen Inc. and SKI are seeking orders enjoining Sandoz from marketing 60 mg and 240 mg generic versions of ERLEADA before the expiration of the relevant patents.
Beginning in June 2025, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., The Regents of the University of California, and Sloan-Kettering Institute for Cancer Research initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Hetero Labs Limited Unit V and Hetero USA, Inc. who filed an ANDA seeking approval to market a 240 mg generic version of ERLEADA before the expiration of certain Orange Book Listed Patents. The following U.S. patents are included in the case: 8,445,507; 8,802,689; 9,338,159; 9,987,261; 9,481,663; 9,884,054; RE49,353; 10,849,888; 10,702,508; 11,963,952; 12,303,493; and 12,303,497.
SPRAVATO
Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc. and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. A trial against Sandoz took place in February 2026. Post-trial briefing is ongoing.
CAPLYTA
Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufacturers who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., MSN Laboratories Private Ltd., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; 12,128,043; 12,409,176; and 12,410,195. In February 2026, Intra-Cellular and MSN Laboratories Private Ltd. entered into a confidential settlement agreement and the case was dismissed. In March 2026, Intra-Cellular and Alkem Laboratories Ltd. entered into a confidential settlement agreement and the case was dismissed.
UPTRAVI
Beginning in September 2025, Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. (collectively, Actelion), and Nippon Shinyaku Co. Ltd. filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Apotex Inc. and Apotex Corp. The following U.S. patents are included in one or more cases: 8,791,122; and 9,284,280. In April 2026, Actelion, Nippon Shinyaku Co. Ltd., Apotex Inc., and Apotex Corp. entered into a confidential settlement agreement resolving the action.
CARVYKTI
In January 2026, 2seventy bio, Inc. filed suit in the Unified Patent Court, Local Division of Brussels, against the Company, Janssen Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag NV, Janssen Biologics B.V., Janssen-Cilag B.V., Janssen-Cilag GmbH, Janssen-Cilag, Janssen-Cilag SpA, Janssen-Cilag A/S, Janssen-Cilag Aktiebolag, Janssen-Cilag Farmaceutica Lda., Legend Biotech Corporation, Legend Biotech USA Inc., Legend Biotech Ireland Limited, and Legend Biotech Belgium BV alleging that the manufacture and sale of CARVYKTI infringes EU Patent No. 3 689 383. In the suit, 2seventy bio, Inc. seeks damages and an injunction.
MedTech
In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the United States District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents. Maquet counterclaimed for infringement against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. The following U.S. patents are at issue: 8,888,728; 9,327,068; 9,545,468; 9,561,314; and 9,597,437. In February 2026, the U.S. Court of Appeals for the Federal Circuit remanded the case after considering the District Court's claim constructions. Discovery will begin based on the altered constructions.

In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH in the United States District Court for the District of Massachusetts alleging that certain Impella products infringe Maquet patents. U.S. Patent No. 10,238,783 remains in the suit, and trial is scheduled to begin in May 2026.

Government proceedings
Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state, and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.
MedTech
In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry. In the pending qui tam action, the Government filed a notice of declination, and the court ordered the complaint unsealed in February 2026. In March 2026, relators voluntarily dismissed their complaint without prejudice, and the court entered an order of dismissal.

Innovative Medicine
In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. In June 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company challenged the verdict on the off-label claims in post-trial briefing. In March 2025, the court dismissed the state law portion of the claims but entered judgment on the federal claims. The Company appealed the remainder of the verdict to the Third Circuit. The federal government has intervened for the limited purpose of defending the qui tam provision of the False Claims Act. Briefing is complete and oral argument was held in March 2026. A decision is pending. In April 2026, the Third Circuit ordered the parties to engage in mediation.

In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice (DOJ) regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the DOJ notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The DOJ had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. The Court will hear argument on the parties’ summary judgment motions in May 2026. The Court has scheduled a trial date in November 2026.
General litigation
The Company or its subsidiaries regularly face claims in legal proceedings related to contracts, trade secrets, antitrust, unfair competition, consumer protection, and environmental issues, the most significant of which are listed below. Although the Company and its subsidiaries believe that they have substantial defenses to these cases, there can be no assurance as to the outcome of these matters. A loss in any of these cases could require the payment of damages, injunctions, and/or other relief.

In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including the Company and certain of its subsidiaries in the United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In June 2024, the
Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit for reconsideration. In January 2026, the D.C. Circuit affirmed its reversal of the District Court's dismissal of the complaint. In February 2026, the defendants sought rehearing en banc with the D.C. Circuit.

In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson in the United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company’s prescription-drug benefits program. The complaint seeks damages and other relief. In March 2025, plaintiffs filed a second amended complaint. In November 2025, the court granted defendants' motion to dismiss plaintiffs' fiduciary duty claims. Plaintiffs voluntarily withdrew their remaining claim, and the court entered final judgment in defendants' favor in January 2026. Plaintiffs have appealed to the United States Court of Appeals for the Third Circuit.

MedTech
In October 2020, Fortis Advisors LLC, in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon’s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the court granted in part and denied in part defendants’ motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. Trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. In January 2026, the Delaware Supreme Court reversed in part and affirmed in part the Chancery Court's decision, including a $0.8 billion judgment, inclusive of interest, against the Company that was accrued in the fiscal fourth quarter of 2025 and subsequently paid in January 2026.

In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In May 2025, a jury returned its verdict in favor of Innovative Health. In August 2025, the court issued a permanent injunction concerning BWI's business practices. BWI appealed both the jury verdict and the permanent injunction. In February 2026, BWI filed its opening brief.

Innovative Medicine

In October 2018, two separate putative class actions were filed against Actelion Pharmaceuticals Ltd., Actelion Pharmaceuticals US, Inc. and Actelion Clinical Research, Inc. (collectively, Actelion) in the United States District Court for the District of Maryland and the United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiffs' motion for class certification. In February 2026, the parties agreed to settle the matter, which is pending court approval.

In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss plaintiffs' amended complaint. In December 2025, the court granted plaintiffs' motion for class certification. In January 2026, the court granted summary judgment for Janssen on plaintiffs' claim regarding patents obtained through the acquisition of Momenta Pharmaceuticals, Inc. in 2020.

In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC, and the Company (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss. Daubert briefing is ongoing.

In August 2025, Xoma Corporation (Xoma) filed a complaint against Janssen Biotech, Inc. (Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges breach of contract, unjust enrichment, and declaratory relief claims against Janssen regarding the alleged failure to obtain a license from Xoma in connection with Janssen's commercialization of TREMFYA. In December 2025, the court denied Janssen's motion to dismiss.
v3.26.1
Restructuring
 3 Months Ended
Mar. 29, 2026
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The pre-tax restructuring expense in the fiscal first quarter of 2026 primarily included costs related to product exits. Total project costs of approximately $0.3 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be substantially completed by the end of fiscal year 2026.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal first quarter of 2026 primarily included costs related to market and product exits. The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments as well as market and product exits. Total project costs of approximately $0.8 billion have been recorded since the restructuring was announced and the program was substantially completed in the fiscal year 2025.
The following table summarizes the restructuring expenses for 2026 and 2025:
(Pre-tax Dollars in Millions)Q1 2026Q1 2025
MedTech Segment Surgery franchise(1)
$55
—
MedTech Segment Orthopaedics franchise(2)
7
55
Total Programs
$62
55
(1)Included $30 million in Restructuring, $20 million in Cost of products sold and $5 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2026.
(2)Included $17 million in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2025.
Restructuring reserves as of March 29, 2026 and December 28, 2025 were insignificant.
v3.26.1
Insider Trading Arrangements
 3 Months Ended
Mar. 29, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 29, 2026
Accounting Policies [Abstract]  
New and Recently Adopted Accounting Standards
There were no new material accounting standards issued in the fiscal first quarter of 2026.
Cash and Cash Equivalents
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
v3.26.1
Inventories (Tables)
 3 Months Ended
Mar. 29, 2026
Inventory Disclosure [Abstract]  
Summary of Inventories
(Dollars in Millions)March 29, 2026December 28, 2025
Raw materials and supplies$2,6122,530
Goods in process4,0333,828
Finished goods7,9387,833
Total inventories$14,58314,191
v3.26.1
Intangible assets and goodwill (Tables)
 3 Months Ended
Mar. 29, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
(Dollars in Millions)March 29, 2026December 28, 2025
Intangible assets with definite lives:  
Patents and trademarks — gross$58,51559,156
Less accumulated amortization
(32,939)
(32,507)
Patents and trademarks — net
$25,576
26,649
Customer relationships and other intangibles — gross21,34021,361
Less accumulated amortization(15,156)(14,998)
Customer relationships and other intangibles — net(1)
$6,184
6,363
Intangible assets with indefinite lives:  
Trademarks1,7661,772
Purchased in-process research and development15,53515,619
Total intangible assets — net$49,06150,403
(1)The majority is comprised of customer relationships
Goodwill
Goodwill as of March 29, 2026 was allocated by segment of business as follows:
(Dollars in Millions)
Innovative
Medicine
MedTechTotal
Goodwill at December 28, 2025
$14,96733,80548,772
Goodwill, related to acquisitions———
Goodwill, related to divestitures———
Currency translation/Other
(155)
(59)
(214)
Goodwill at March 29, 2026
$14,81233,74648,558
Intangible Asset Amortization Expense
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20262027202820292030
$5,1004,4003,7003,6003,500
v3.26.1
Fair value measurements (Tables)
 3 Months Ended
Mar. 29, 2026
Fair Value Disclosures [Abstract]  
Summary of Derivative Activity
The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended March 29, 2026 and March 30, 2025, net of tax:


March 29, 2026March 30, 2025
(Dollars in Millions)Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
    Hedged items$———36————188—
    Derivatives designated as hedging instruments———(36)————(188)—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———47————49—
   Amount of gain or (loss) recognized in AOCI———47————49—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income 173(5)—(2)(1)101——
   Amount of gain or (loss) recognized in AOCI (7)(195)37—253105(36)—(11)
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———83————83—
   Amount of gain or (loss) recognized in AOCI$———16————566—
The following table is the effect of net investment hedges for the fiscal first quarters ended in 2026 and 2025:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)March 29, 2026March 30, 2025March 29, 2026March 30, 2025
Debt
$213
(316)
Interest (income) expense
—
—
Cross Currency interest rate swaps
$217
840
Interest (income) expense
—
—
Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet
As of March 29, 2026, and December 28, 2025, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is includedCarrying Amount of the Hedged Liability
Cumulative Amount of Fair Value
Hedging Gain/ (Loss) Included in the
Carrying Amount of the Hedged Liability
(Dollars in Millions)March 29, 2026December 28, 2025March 29, 2026December 28, 2025
Long-term Debt$7,3608,318(647)(694)
Schedule of Effect of Derivatives not Designated as Hedging Instruments
The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2026 and 2025:
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)Location of
Gain /(Loss)
Recognized in
Income on Derivative		Fiscal First Quarter Ended
Derivatives Not Designated as Hedging InstrumentsMarch 29, 2026March 30, 2025
Foreign Exchange ContractsOther (income) expense$(65)62
Summary of Activity Related to Equity Investments
The following table is a summary of the activity related to equity investments:
December 28, 2025March 29, 2026
(Dollars in Millions)Carrying Value
Changes in Fair Value Reflected in Net Income (1)
(Sales)/ Purchases/Other (2)
Carrying ValueNon Current Other Assets
Equity Investments with readily determinable value$66543(5)703703
Equity Investments without readily determinable value$91046(68)888888
(1)Recorded in Other (income)/expense, net
(2)Other includes impact of currency
Financial Assets and Liabilities at Fair Value
The Company’s significant financial assets and liabilities measured at fair value as of March 29, 2026 and December 28, 2025 were as follows:
 March 29, 2026December 28, 2025
(Dollars in Millions)Level 1Level 2Level 3Total
Total(1)
Derivatives designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $—549—549686
Interest rate contracts(2)
—610—610589
Total —1,159—1,1591,275
Liabilities:     
Forward foreign exchange contracts —418—418413
Interest rate contracts(2)
—5,386—5,3865,848
Total —5,804—5,8046,261
Derivatives not designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts —47—4738
Liabilities:     
Forward foreign exchange contracts —49—4946
Other Investments:
Equity investments(3)
703——703665
Debt securities(4)
—6,675—6,6752,854
Other Liabilities:
Contingent consideration(5)
$——754754753
Gross to Net Derivative ReconciliationMarch 29, 2026December 28, 2025
(Dollars in Millions)
Total Gross Assets$1,2061,313
Credit Support Agreement (CSA)(1,094)(1,308)
Total Net Asset1125
Total Gross Liabilities5,8536,307
Credit Support Agreement (CSA)(5,829)(5,903)
Total Net Liabilities$24404
Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended March 29, 2026 and March 30, 2025 is as follows:
March 29, 2026March 30, 2025
(Dollars in Millions)
Beginning Balance$7531,217
Changes in estimated fair value(6)
114
Additions——
Payments——
Ending Balance$7541,231
(1)2025 assets and liabilities are all classified as Level 2 with the exception of equity investments of $665 million, which are classified as Level 1 and contingent consideration of $753 million, classified as Level 3.
(2)Includes cross currency interest rate swaps and interest rate swaps.
(3)Classified as non-current other assets.
(4)Classified within cash equivalents and current marketable securities.
(5)Classified as non-current other liabilities.
(6)Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
Marketable Securities
The Company's cash, cash equivalents and current marketable securities as of March 29, 2026 comprised:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash
$3,310
3,310
3,310
—
U.S. reverse repurchase agreements
6,253
6,253
6,253
—
Money market funds
5,089
5,089
5,089
—
Time deposits(1)
724
724
724
—
   Subtotal
15,376
15,376
15,376
—
​
U.S. Gov’t securities
6,225
6,225
6,207
18
Other sovereign securities
234
234
76
158
Corporate and other debt securities
216
216
29
187
   Subtotal available for sale debt(2)
$6,675
6,675
6,312
363
Total cash, cash equivalents and current marketable securities
$22,051
22,051
21,688
363
(1)Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities
The contractual maturities of the available for sale securities as of March 29, 2026 are as follows:
(Dollars in Millions)Cost BasisFair Value
Due within one year
$6,659
6,659
Due after one year through five years
16
16
Due after five years through ten years
—
—
Total debt securities
$6,675
6,675
Financial Liabilities not Measured at Fair Value
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 29, 2026:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Financial Liabilities  
Current Debt$17,460
17,455
Non-Current Debt  
0.95% Notes due 2027
1,4991,439
2.90% Notes due 2028
1,4991,470
1.150% Notes due 2028 (750MM Euro 1.1541)
863826
4.55% Notes due 2028
749758
4.80% Notes due 2029
1,1471,174
6.95% Notes due 2029
299327
2.70% Notes due 2029 (600MM Euro 1.1541)
692685
1.30% Notes due 2030
1,7021,544
4.70% Notes due 2030
9961,018
4.90% Notes due 2031
1,1461,180
3.20% Notes due 2032 (700MM Euro 1.1541)
805798
4.85% Notes due 2032
1,2431,275
4.95% Notes due 2033
499518
4.375% Notes due 2033
853845
3.050% Notes due 2033 (700MM Euro 1.1541)
806786
4.95% Notes due 2034

847882
1.650% Notes due 2035 (1.5B Euro 1.1541)
1,7221,463
5.00% Notes due 2035
1,2441,275
3.35% Notes due 2036 (800MM Euro 1.1541)

919892
3.587% Notes due 2036
925903
5.95% Notes due 2037
9951,085
3.625% Notes due 2037
1,4141,333
3.350% Notes due 2037 (1.0B Euro 1.1541)
1,1511,100
3.40% Notes due 2038
994855
5.85% Notes due 2038
697754
4.50% Notes due 2040
542512
2.10% Notes due 2040
902687
4.85% Notes due 2041
298292
4.50% Notes due 2043
497453
3.55% Notes due 2044 (1.0B Euro 1.1541)
1,1441,057
3.60% Notes due 2045 (700MM Euro 1.1541)
802741
3.73% Notes due 2046
1,9801,565
3.75% Notes due 2047
877778
3.50% Notes due 2048
744555
2.25% Notes due 2050
864572
5.25% Notes due 2054

843831
3.70% Notes due 2055 (1.0B Euro 1.1541)
1,1481,027
2.45% Notes due 2060
1,118660
Other6277
Total Non-Current Debt$37,52734,992
v3.26.1
Pensions and other benefit plans (Tables)
 3 Months Ended
Mar. 29, 2026
Retirement Benefits [Abstract]  
Components of Net Periodic Benefit Cost
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal First Quarter Ended
 Retirement PlansOther Benefit Plans
(Dollars in Millions)March 29, 2026March 30, 2025March 29, 2026March 30, 2025
Service cost$2362148072
Interest cost3603515254
Expected return on plan assets(639)(587)(2)(2)
Amortization of prior service cost/(credit)
(46)(46)——
Recognized actuarial (gains)/losses
69
83
26
16
Net periodic benefit cost/(credit)$(20)15156140
v3.26.1
Accumulated other comprehensive income (Tables)
 3 Months Ended
Mar. 29, 2026
Equity [Abstract]  
Components of Accumulated Other Comprehensive Income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions)
Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit
Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income/(Loss)
December 28, 2025$(13,947)—(693)(290)(14,930)
Net change334—39(274)99
March 29, 2026(13,613)—(654)(564)(14,831)
v3.26.1
Earnings per share (Tables)
 3 Months Ended
Mar. 29, 2026
Earnings Per Share [Abstract]  
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
 Fiscal First Quarter Ended
(Shares in Millions)March 29, 2026March 30, 2025
Basic net earnings per share$2.174.57
Average shares outstanding — basic2,408.72,407.2
Potential shares exercisable under stock option plans100.669.0
Less: shares which could be repurchased under treasury stock method(64.1)(52.4)
Average shares outstanding — diluted2,445.22,423.8
Diluted net earnings per share$2.144.54
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock.
3.560.9
v3.26.1
Segments of business and geographic areas (Tables)
 3 Months Ended
Mar. 29, 2026
Segment Reporting [Abstract]  
Sales By Segment Of Business
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,6153,01320.0 %
International
3,3582,66426.0 
Worldwide
6,9735,67822.8 
DARZALEX
U.S.
2,2081,82920.7 
International
1,7561,40924.7 
Worldwide
3,9643,23722.5 
CARVYKTI
U.S.
43331836.2
International
16451*
Worldwide
59736962.1
TECVAYLI
U.S.
12710520.6 
International
744663.1
Worldwide
20215133.5 
TALVEY
U.S.
1016848.5 
International
5118*
Worldwide
1528676.7 
RYBREVANT/ LAZCLUZE
U.S.
17511355.1
International
8228*
Worldwide
25714182.7
ERLEADA
U.S.
34229217.3 
International
60747926.7 
Worldwide
94977123.1 
IMBRUVICA
U.S.
143235(39.1)
International
5174749.1 
Worldwide
660709(6.9)
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER ONCOLOGY(1)
U.S.
855458.8 
International
106160(33.9)
Worldwide
192214(10.6)
Immunology
U.S.
1,8552,196(15.5)
International
1,5241,5100.9 
Worldwide
3,3803,707(8.8)
TREMFYA
U.S.
1,04259973.9 
International
56635658.9 
Worldwide
1,60895668.3 
SIMPONI / SIMPONI ARIA
U.S.
269292(7.8)
International
3783663.0 
Worldwide
647659(1.7)
REMICADE
U.S.
269314(14.4)
U.S. Exports
181078.6 
International
136143(4.8)
Worldwide
422467(9.5)
STELARA
U.S.
220981(77.6)
International
435644(32.4)
Worldwide
6561,625(59.7)
OTHER IMMUNOLOGY
U.S.
381*
International
90*
Worldwide
461*
Neuroscience
U.S.
1,49496854.3 
International
6816790.3 
Worldwide
2,1751,64732.0 
SPRAVATO
U.S.
40627647.0 
International
614342.4 
Worldwide
46832046.4 
CAPLYTA(2)
U.S.
270—*
International
——— 
Worldwide
270—*
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
75862521.2 
International
2802771.1 
Worldwide
1,03890315.0 
CONCERTA / methylphenidate
U.S.
2238(43.4)
International
1151104.3 
Worldwide
136148(8.0)
OTHER NEUROSCIENCE
U.S.
382832.6 
International
224248(9.7)
Worldwide
262277(5.4)
Pulmonary Hypertension (PH)
U.S.
83174411.7 
International
3042818.2 
Worldwide
1,1351,02510.7 
UPTRAVI
U.S.3853655.4 
International988614.3 
Worldwide4834517.1 
OPSUMIT/OPSYNVI
U.S.43336319.3 
International1721598.7 
Worldwide60652216.1 
OTHER PULMONARY HYPERTENSION
U.S.
1215(21.1)
International3437(8.3)
Worldwide 4652(12.1)
Infectious Diseases (ID)
U.S.
3423158.6 
International
54748712.2 
Worldwide
88980210.8 
EDURANT / rilpivirine
U.S.
78(13.1)
International
40235014.8 
Worldwide
40935814.1 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
3343059.5 
International
1099811.2 
Worldwide
44340310.0 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER INFECTIOUS DISEASES
U.S.
12(56.9)
International
3639(8.3)
Worldwide
3741(10.4)
Cardiovascular / Metabolism / Other (CVM)
U.S.734855(14.2)
International142158(10.4)
Worldwide8761,013(13.6)
XARELTO
U.S.642690(7.0)
International——— 
Worldwide642690(7.0)
OTHER
U.S.91165(44.5)
International142158(10.4)
Worldwide233323(27.8)
Total PH, ID, CVM
U.S.1,9071,914(0.4)
International9939267.1 
Worldwide2,8992,8402.1 
TOTAL INNOVATIVE MEDICINE
 
 
U.S.8,8718,0929.6 
International6,5555,78113.4 
Worldwide15,42613,87311.2 
MEDTECH
Cardiovascular
U.S.1,3991,26110.9 
International97884216.1 
Worldwide2,3772,10313.0 
ELECTROPHYSIOLOGY
U.S.7366847.6 
International75363818.0 
Worldwide1,4891,32312.6 
ABIOMED
U.S.38933914.5 
International1008123.5 
Worldwide48842016.3 
SHOCKWAVE
U.S.24220617.8 
International635221.3 
Worldwide30525818.5 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER CARDIOVASCULAR
U.S.32320.7 
International6272(13.4)
Worldwide94103(9.1)
Surgery
U.S.
1,046
1,002
4.4 
International
1,465
1,394
5.1 
Worldwide
2,511
2,396
4.8 
ADVANCED
U.S.4774574.2 
International6466164.9 
Worldwide1,1231,0734.6 
GENERAL
U.S.5695444.5 
International8197785.2 
Worldwide1,3881,3234.9 
Vision
U.S.5795662.4 
International78571310.1 
Worldwide1,3651,2796.7 
CONTACT LENSES / OTHER
U.S.4684523.7 
International5014677.2 
Worldwide9699195.5 
SURGICAL
U.S.111114(2.9)
International28524615.6 
Worldwide3963619.7 
Orthopaedics*
U.S.
1,435
1,384
3.7 
International
948
857
10.6 
Worldwide
2,383
2,241
6.3 
HIPS
U.S.
277
263
5.2 
International
159
146
8.9 
Worldwide
436
409
6.5 
KNEES
U.S.
239
231
3.3 
International
181
158
14.6 
Worldwide
420
389
7.9 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
TRAUMA
U.S.
532
502
6.1 
International
301
270
11.4 
Worldwide
833
772
8.0 
SPINE, SPORTS & OTHER
U.S.
387
388
(0.1)
International
307
283
8.4 
Worldwide
694
671
3.5 
TOTAL MEDTECH  
U.S.4,4594,2135.9 
International4,1773,8079.7 
Worldwide8,6368,0207.7 
WORLDWIDE   
U.S.13,33012,3058.3 
International10,7329,58811.9 
Worldwide$24,06221,8939.9%
*    Percentage greater than 100% or not meaningful
(1) Includes the sales of ZYTIGA which were previously disclosed separately
(2) Acquired with Intra-Cellular Therapies on April 2, 2025
Operating Profit by Segment of Business
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$15,4268,63613,8738,020
Cost of products sold4,3903,7014,0203,326
Selling, marketing and administrative2,9182,9062,2612,656
Research and development expense2,8137142,548677
Other segment items (3)
(12)76(166)(60)
Segment income before tax$5,3171,2396,5565,2101,4216,631
(Income)/Expense not allocated to segments (4)
566(7,000)
Earnings before provision for taxes on income$5,990$13,631
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.8 billion and $0.6 billion in the fiscal first quarters of 2026 and 2025, respectively.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion in both the fiscal first quarters of 2026 and 2025.
•Orthopaedics Separation related charge of $0.1 billion in the fiscal first quarter of 2026.
•Acquisition and integration related expense of $0.1 billion in the fiscal first quarter of 2025, primarily related to Shockwave.
(3)    Other segment items for each reportable segment include other income and expense (gains and losses on divestitures and gains and losses on sale of assets), restructuring activities and impairment charges related to in-process research and development
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2026 includes charges for talc matters of $0.3 billion. The fiscal first quarter of 2025 includes approximately $7.0 billion related to the talc reserve reversal.
Identifiable Assets
(Dollars in Millions)March 29, 2026December 28, 2025
Innovative Medicine$78,118
78,057
MedTech86,17986,482
Total
164,297
164,539
General corporate (1)
36,59734,671
Worldwide total$200,894199,210
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
Fiscal Three Months Ended
(Dollars in Millions)March 29, 2026March 30, 2025March 29, 2026March 30, 2025
Innovative Medicine$508276$1,036884
MedTech509480903836
Segments total1,0177561,9391,720
General corporate32396552
Worldwide total$1,049795$2,0041,772
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
Sales by geographic area
 Fiscal First Quarter Ended
(Dollars in Millions)March 29, 2026March 30, 2025Percent
Change
United States$13,33012,3058.3%
Europe5,8485,11014.5 
Western Hemisphere, excluding U.S.1,2931,16710.8 
Asia-Pacific, Africa3,5913,3118.5 
Total$24,06221,8939.9%
v3.26.1
Restructuring (Tables)
 3 Months Ended
Mar. 29, 2026
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Reserve
The following table summarizes the restructuring expenses for 2026 and 2025:
(Pre-tax Dollars in Millions)Q1 2026Q1 2025
MedTech Segment Surgery franchise(1)
$55
—
MedTech Segment Orthopaedics franchise(2)
7
55
Total Programs
$62
55
(1)Included $30 million in Restructuring, $20 million in Cost of products sold and $5 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2026.
(2)Included $17 million in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2025.
v3.26.1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Billions
Mar. 29, 2026
Dec. 28, 2025
Accounting Policies [Abstract]    
Supplier finance program, payment timing, period 90 days  
Supplier finance program, obligation $ 0.7 $ 0.8
v3.26.1
Inventories (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 28, 2025
Inventory Disclosure [Abstract]    
Raw materials and supplies $ 2,612 $ 2,530
Goods in process 4,033 3,828
Finished goods 7,938 7,833
Total inventories $ 14,583 $ 14,191
v3.26.1
Intangible assets and goodwill (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 28, 2025
Intangible assets with indefinite lives:    
Total intangible assets — net $ 49,061 $ 50,403
Trademarks    
Intangible assets with indefinite lives:    
Total intangible assets with indefinite lives 1,766 1,772
Purchased In-Process Research And Development    
Intangible assets with indefinite lives:    
Total intangible assets with indefinite lives 15,535 15,619
Patents And Trademarks    
Intangible assets with definite lives:    
Finite-lived intangible assets, gross 58,515 59,156
Less accumulated amortization (32,939) (32,507)
Finite-lived intangible assets, net 25,576 26,649
Customer relationships and other intangible assets    
Intangible assets with definite lives:    
Finite-lived intangible assets, gross 21,340 21,361
Less accumulated amortization (15,156) (14,998)
Finite-lived intangible assets, net $ 6,184 $ 6,363
v3.26.1
Intangible assets and goodwill - Goodwill By Segment (Details)
$ in Millions
 3 Months Ended
Mar. 29, 2026
USD ($)
Goodwill [Roll Forward]  
Goodwill Beginning of Period $ 48,772
Goodwill, related to acquisitions 0
Goodwill, related to divestitures 0
Currency translation/Other (214)
Goodwill End of Period 48,558
Innovative Medicine  
Goodwill [Roll Forward]  
Goodwill Beginning of Period 14,967
Goodwill, related to acquisitions 0
Goodwill, related to divestitures 0
Currency translation/Other (155)
Goodwill End of Period 14,812
MedTech  
Goodwill [Roll Forward]  
Goodwill Beginning of Period 33,805
Goodwill, related to acquisitions 0
Goodwill, related to divestitures 0
Currency translation/Other (59)
Goodwill End of Period $ 33,746
v3.26.1
Intangible assets and goodwill - Narrative (Details) - USD ($)
$ in Billions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Finite-Lived Intangible Assets [Line Items]    
Amortization expense of amortizable intangible assets $ 1.2 $ 1.1
Patents And Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 12 years  
Customer relationships and other intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 19 years  
v3.26.1
Intangible assets and goodwill - Intangible Asset Amortization Expense (Details)
$ in Millions
Mar. 29, 2026
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2026 $ 5,100
2027 4,400
2028 3,700
2029 3,600
2030 $ 3,500
v3.26.1
Fair value measurements - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 29, 2026
Dec. 28, 2025
Derivative [Line Items]    
Accumulated other comprehensive loss on derivatives, after tax $ (600)  
Hedging exposure 18 months  
Weighted average interest rate on non-current debt 3.56%  
Excess of carrying value over fair value of debt   $ 1,700
Current Debt $ 17,460 8,495
Cash and Cash Equivalents 21,688 19,709
Money market funds | Fair Value, Inputs, Level 1 [Member]    
Derivative [Line Items]    
Cash and Cash Equivalents 5,089 5,993
Commercial Paper    
Derivative [Line Items]    
Current Debt $ 15,700 $ 6,500
Weighted average interest rate 3.67% 3.81%
Term 2 months 2 months
Forward foreign exchange contracts    
Derivative [Line Items]    
Collateral already posted, aggregate fair value $ 4,700  
Derivative, notional amount 43,900 $ 40,600
Cross currency interest rate swaps    
Derivative [Line Items]    
Derivative, notional amount 37,900 38,900
Interest Rate Swap    
Derivative [Line Items]    
Derivative, notional amount $ 8,000 $ 8,000
v3.26.1
Fair value measurements - Summary of Derivative Activity (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0
Cross currency interest rate swaps | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income 0 0
Fair Value Hedging | Interest Rate Swap | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Fair Value Hedging | Interest Rate Swap | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Fair Value Hedging | Interest Rate Swap | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 36 188
Amount of gain or (loss) recognized in AOCI (36) (188)
Fair Value Hedging | Interest Rate Swap | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 47 49
Amount of gain or (loss) recognized in AOCI 47 49
Net Investment Hedging | Net Investment Hedging | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI (7) 3
Amount of gain or (loss) reclassified from AOCI into income 1 (1)
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI (195) 105
Amount of gain or (loss) reclassified from AOCI into income 73 10
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 37 (36)
Amount of gain or (loss) reclassified from AOCI into income (5) 1
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 25 (11)
Amount of gain or (loss) reclassified from AOCI into income (2) 0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 16 566
Amount of gain or (loss) reclassified from AOCI into income 83 83
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0
v3.26.1
Fair value measurements - Derivatives, Balance Sheet Location (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 28, 2025
Derivative [Line Items]    
Carrying Amount of the Hedged Liability $ 5,853 $ 6,307
Designated as Hedging Instrument    
Derivative [Line Items]    
Carrying Amount of the Hedged Liability 7,360 8,318
Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability $ (647) $ (694)
v3.26.1
Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Not Designated as Hedging Instrument | Forward foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain/(Loss) Recognized In Income on Derivative $ (65) $ 62
v3.26.1
Fair value measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Derivative Instruments, Gain (Loss) [Line Items]    
Gain/(Loss) Recognized In Accumulated OCI $ 213 $ (316)
Other Income Expense Net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cross Currency Interest Rate Contract    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain/(Loss) Recognized In Accumulated OCI 217 840
Cross Currency Interest Rate Contract | Other Income Expense Net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0
v3.26.1
Fair value measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Dec. 28, 2025
Equity Investment [Roll Forward]    
Non Current Other Assets $ 14,105 $ 14,368
Equity Securities | Equity Investments with readily determinable value    
Equity Investment [Roll Forward]    
Carrying value, beginning of period 665  
Equity, Fair Value Adjustment 43  
Sales/ Purchases/Other (5)  
Carrying value, end of period 703  
Non Current Other Assets 703  
Equity Securities | Equity Investments without readily determinable value    
Equity Investment [Roll Forward]    
Carrying value, beginning of period 910  
Equity, Fair Value Adjustment 46  
Sales/ Purchases/Other (68)  
Carrying value, end of period 888  
Non Current Other Assets $ 888  
v3.26.1
Fair value measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Dec. 28, 2025
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets $ 1,159    
Derivatives designated as hedging instruments : Liabilities 5,804    
Available-for-sale Securities, Equity Securities 703   $ 665
Available-for-sale Securities 6,675   2,854
Contingent consideration 754   753
Total Gross Assets 1,206   1,313
Credit Support Agreement (CSA) (1,094)   (1,308)
Total Net Asset 112   5
Total Gross Liabilities 5,853   6,307
Credit Support Agreement (CSA) (5,829)   (5,903)
Total Net Liabilities 24   404
Beginning Balance 753 $ 1,217  
Changes in estimated fair value(6) 1 14  
Additions 0 0  
Payments 0 0  
Ending Balance 754 $ 1,231  
Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Available-for-sale Securities, Equity Securities 703   665
Available-for-sale Securities 0    
Contingent consideration 0    
Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 1,159   1,275
Derivatives designated as hedging instruments : Liabilities 5,804   6,261
Available-for-sale Securities, Equity Securities 0    
Available-for-sale Securities 6,675    
Contingent consideration 0    
Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Available-for-sale Securities, Equity Securities 0    
Available-for-sale Securities 0    
Contingent consideration 754   753
Interest Rate Contract      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 610    
Derivatives designated as hedging instruments : Liabilities 5,386    
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Interest Rate Contract | Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 610   589
Derivatives designated as hedging instruments : Liabilities 5,386   5,848
Interest Rate Contract | Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Forward foreign exchange contracts      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 549    
Derivatives designated as hedging instruments : Liabilities 418    
Derivatives not designated as hedging instruments : Assets 47    
Derivatives not designated as hedging instruments : Liabilities 49    
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Derivatives not designated as hedging instruments : Assets 0    
Derivatives not designated as hedging instruments : Liabilities 0    
Forward foreign exchange contracts | Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 549   686
Derivatives designated as hedging instruments : Liabilities 418   413
Derivatives not designated as hedging instruments : Assets 47   38
Derivatives not designated as hedging instruments : Liabilities 49   $ 46
Forward foreign exchange contracts | Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Derivatives not designated as hedging instruments : Assets 0    
Derivatives not designated as hedging instruments : Liabilities $ 0    
v3.26.1
Fair value measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 28, 2025
Mar. 29, 2026
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Estimated Fair Value $ 2,854 $ 6,675
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 19,709 21,688
Marketable securities 393 363
Total cash, cash equivalents and current marketable securities, Carrying Amount   22,051
Total cash, cash equivalents and current marketable securities, Estimated Fair Value   22,051
Excess of carrying value over fair value of debt $ 1,700  
Held-to-maturity Securities    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   15,376
Held-to-maturity Securities - Estimated Fair Value   15,376
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   15,376
Marketable securities   0
Held-to-maturity Securities | Cash    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   3,310
Held-to-maturity Securities - Estimated Fair Value   3,310
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   3,310
Marketable securities   0
Held-to-maturity Securities | U.S. reverse repurchase agreements    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   6,253
Held-to-maturity Securities - Estimated Fair Value   6,253
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   6,253
Marketable securities   0
Held-to-maturity Securities | Money market funds    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   5,089
Held-to-maturity Securities - Estimated Fair Value   5,089
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   5,089
Marketable securities   0
Held-to-maturity Securities | Time deposits(1)    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   724
Held-to-maturity Securities - Estimated Fair Value   724
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   724
Marketable securities   0
Available-for-sale Securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   6,675
Available-for-sale Securities - Estimated Fair Value   6,675
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   6,312
Marketable securities   363
Available-for-sale Securities | U.S. Gov’t securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   6,225
Available-for-sale Securities - Estimated Fair Value   6,225
Available-for-sale Securities | Non-U.S. sovereign securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   234
Available-for-sale Securities - Estimated Fair Value   234
Available-for-sale Securities | Corporate debt securities(1)    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   216
Available-for-sale Securities - Estimated Fair Value   216
Available-for-sale Securities | Non-U.S. sovereign securities    
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   76
Marketable securities   158
Available-for-sale Securities | Corporate debt securities(1)    
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   29
Marketable securities   187
Available-for-sale Securities | U.S. Gov’t securities    
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   6,207
Marketable securities   $ 18
v3.26.1
Fair value measurements - Schedule of Available for Sale Securities Maturities (Details)
$ in Millions
Mar. 29, 2026
USD ($)
Cost Basis  
Due within one year $ 6,659
Due after one year through five years 16
Due after five years through ten years 0
Total debt securities 6,675
Fair Value  
Due within one year 6,659
Due after one year through five years 16
Due after five years through ten years 0
Total debt securities $ 6,675
v3.26.1
Fair value measurements - Financial Liabilities not Measured at Fair Value (Details)
$ in Millions
Mar. 29, 2026
USD ($)
Mar. 29, 2026
EUR (€)
Dec. 28, 2025
USD ($)
Financial Liabilities      
Current Debt $ 17,460   $ 8,495
Non-Current Debt      
Non-Current Debt 37,527   $ 39,438
Carrying Amount      
Financial Liabilities      
Current Debt 17,460    
Non-Current Debt      
Non-Current Debt 37,527    
Estimated Fair Value      
Financial Liabilities      
Current Debt 17,455    
Non-Current Debt      
Non-Current Debt $ 34,992    
0.95% Notes due 2027      
Non-Current Debt      
Stated interest rate (as a percent) 0.95% 0.95%  
0.95% Notes due 2027 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,499    
0.95% Notes due 2027 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,439    
2.90% Notes due 2028      
Non-Current Debt      
Stated interest rate (as a percent) 2.90% 2.90%  
2.90% Notes due 2028 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,499    
2.90% Notes due 2028 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,470    
1.150% Notes due 2028 (750MM Euro 1.1541)      
Non-Current Debt      
Stated interest rate (as a percent) 1.15% 1.15%  
Debt instrument, face amount | €   € 750,000,000  
Foreign exchange rate 1.1541 1.1541  
1.150% Notes due 2028 (750MM Euro 1.1541) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 863    
1.150% Notes due 2028 (750MM Euro 1.1541) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 826    
4.55% Notes Due 2029      
Non-Current Debt      
Stated interest rate (as a percent) 4.55% 4.55%  
4.55% Notes Due 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 749    
4.55% Notes Due 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 758    
4.80% Notes due 2029      
Non-Current Debt      
Stated interest rate (as a percent) 4.80% 4.80%  
4.80% Notes due 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,147    
4.80% Notes due 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,174    
6.95% Notes due 2029      
Non-Current Debt      
Stated interest rate (as a percent) 6.95% 6.95%  
6.95% Notes due 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 299    
6.95% Notes due 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 327    
2.700% Notes Due February 2029      
Non-Current Debt      
Stated interest rate (as a percent) 2.70% 2.70%  
Debt instrument, face amount | €   € 600,000,000  
Foreign exchange rate 1.1541 1.1541  
2.700% Notes Due February 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 692    
2.700% Notes Due February 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 685    
1.30% Notes due 2030      
Non-Current Debt      
Stated interest rate (as a percent) 1.30% 1.30%  
1.30% Notes due 2030 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,702    
1.30% Notes due 2030 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,544    
4.70% Notes due 2030      
Non-Current Debt      
Stated interest rate (as a percent) 4.70% 4.70%  
4.70% Notes due 2030 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 996    
4.70% Notes due 2030 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,018    
4.90% Notes due 2031      
Non-Current Debt      
Stated interest rate (as a percent) 4.90% 4.90%  
4.90% Notes due 2031 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,146    
4.90% Notes due 2031 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,180    
3.20% Notes due 2032 (700MM Euro 1.0721)      
Non-Current Debt      
Stated interest rate (as a percent) 3.20% 3.20%  
Debt instrument, face amount | €   € 700,000,000  
Foreign exchange rate 1.1541 1.1541  
3.20% Notes due 2032 (700MM Euro 1.0721) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 805    
3.20% Notes due 2032 (700MM Euro 1.0721) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 798    
4.85% Notes Due 2032      
Non-Current Debt      
Stated interest rate (as a percent) 4.85% 4.85%  
4.85% Notes Due 2032 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,243    
4.85% Notes Due 2032 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,275    
4.95% Notes due 2033      
Non-Current Debt      
Stated interest rate (as a percent) 4.95% 4.95%  
4.95% Notes due 2033 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 499    
4.95% Notes due 2033 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 518    
4.375% Notes due 2033      
Non-Current Debt      
Stated interest rate (as a percent) 4.375% 4.375%  
4.375% Notes due 2033 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 853    
4.375% Notes due 2033 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt 845    
3.050% Notes Due February 2033 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 806    
Stated interest rate (as a percent) 3.05% 3.05%  
Debt instrument, face amount | €   € 700,000,000  
Foreign exchange rate 1.1541 1.1541  
3.050% Notes Due February 2033 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 786    
4.95% Notes due 2034      
Non-Current Debt      
Stated interest rate (as a percent) 4.95% 4.95%  
4.95% Notes due 2034 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 847    
4.95% Notes due 2034 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt 882    
1.650% Notes due 2035 (1.5B Euro 1.1541) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,722    
Stated interest rate (as a percent) 1.65% 1.65%  
Debt instrument, face amount | €   € 1,500,000,000  
Foreign exchange rate 1.1541 1.1541  
1.650% Notes due 2035 (1.5B Euro 1.1541) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,463    
5.00% Notes due 2035      
Non-Current Debt      
Stated interest rate (as a percent) 5.00% 5.00%  
5.00% Notes due 2035 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,244    
5.00% Notes due 2035 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,275    
3.35% Notes Due 2036 (800MM Euro 1.0721)      
Non-Current Debt      
Stated interest rate (as a percent) 3.35% 3.35%  
Debt instrument, face amount | €   € 800,000,000  
Foreign exchange rate 1.1541 1.1541  
3.35% Notes Due 2036 (800MM Euro 1.0721) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 919    
3.35% Notes Due 2036 (800MM Euro 1.0721) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 892    
3.587% Notes due 2036      
Non-Current Debt      
Stated interest rate (as a percent) 3.587% 3.587%  
3.587% Notes due 2036 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 925    
3.587% Notes due 2036 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 903    
5.95% Notes due 2037      
Non-Current Debt      
Stated interest rate (as a percent) 5.95% 5.95%  
5.95% Notes due 2037 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 995    
5.95% Notes due 2037 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,085    
3.625% Notes due 2037      
Non-Current Debt      
Stated interest rate (as a percent) 3.625% 3.625%  
3.625% Notes due 2037 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,414    
3.625% Notes due 2037 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,333    
3.350% Notes Due February 2037      
Non-Current Debt      
Stated interest rate (as a percent) 3.35% 3.35%  
Debt instrument, face amount | €   € 1,000,000,000.0  
Foreign exchange rate 1.1541 1.1541  
3.350% Notes Due February 2037 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,151    
3.350% Notes Due February 2037 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,100    
3.40% Notes due 2038      
Non-Current Debt      
Stated interest rate (as a percent) 3.40% 3.40%  
3.40% Notes due 2038 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 994    
3.40% Notes due 2038 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 855    
5.85% Notes due 2038      
Non-Current Debt      
Stated interest rate (as a percent) 5.85% 5.85%  
5.85% Notes due 2038 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 697    
5.85% Notes due 2038 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 754    
4.50% Notes due 2040      
Non-Current Debt      
Stated interest rate (as a percent) 4.50% 4.50%  
4.50% Notes due 2040 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 542    
4.50% Notes due 2040 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 512    
2.10% Notes due 2040      
Non-Current Debt      
Stated interest rate (as a percent) 2.10% 2.10%  
2.10% Notes due 2040 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 902    
2.10% Notes due 2040 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 687    
4.85% Notes due 2041      
Non-Current Debt      
Stated interest rate (as a percent) 4.85% 4.85%  
4.85% Notes due 2041 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 298    
4.85% Notes due 2041 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 292    
4.50% Notes due 2043      
Non-Current Debt      
Stated interest rate (as a percent) 4.50% 4.50%  
4.50% Notes due 2043 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 497    
4.50% Notes due 2043 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 453    
3.55% Notes Due 2044 (1.0B Euro 1.0721)      
Non-Current Debt      
Stated interest rate (as a percent) 3.55% 3.55%  
Debt instrument, face amount | €   € 1,000,000,000.0  
Foreign exchange rate 1.1541 1.1541  
3.55% Notes Due 2044 (1.0B Euro 1.0721) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,144    
3.55% Notes Due 2044 (1.0B Euro 1.0721) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,057    
3.600% Notes Due February 2045      
Non-Current Debt      
Stated interest rate (as a percent) 3.60% 3.60%  
Debt instrument, face amount | €   € 700,000,000  
Foreign exchange rate 1.1541 1.1541  
3.600% Notes Due February 2045 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 802    
3.600% Notes Due February 2045 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 741    
3.73% Notes due 2046      
Non-Current Debt      
Stated interest rate (as a percent) 3.73% 3.73%  
3.73% Notes due 2046 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,980    
3.73% Notes due 2046 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,565    
3.75% Notes due 2047      
Non-Current Debt      
Stated interest rate (as a percent) 3.75% 3.75%  
3.75% Notes due 2047 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 877    
3.75% Notes due 2047 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 778    
3.50% Notes due 2048      
Non-Current Debt      
Stated interest rate (as a percent) 3.50% 3.50%  
3.50% Notes due 2048 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 744    
3.50% Notes due 2048 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 555    
2.25% Notes due 2050      
Non-Current Debt      
Stated interest rate (as a percent) 2.25% 2.25%  
2.25% Notes due 2050 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 864    
2.25% Notes due 2050 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 572    
5.25% Notes due 2054      
Non-Current Debt      
Stated interest rate (as a percent) 5.25% 5.25%  
5.25% Notes due 2054 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 843    
5.25% Notes due 2054 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 831    
3.700% Notes Due February 2055      
Non-Current Debt      
Stated interest rate (as a percent) 3.70% 3.70%  
Debt instrument, face amount | €   € 1,000,000,000.0  
Foreign exchange rate 1.1541 1.1541  
3.700% Notes Due February 2055 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,148    
3.700% Notes Due February 2055 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,027    
2.45% Notes due 2060      
Non-Current Debt      
Stated interest rate (as a percent) 2.45% 2.45%  
2.45% Notes due 2060 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,118    
2.45% Notes due 2060 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt 660    
Other | Carrying Amount      
Non-Current Debt      
Non-Current Debt 62    
Other | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 77    
v3.26.1
Income taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Income Tax Contingency    
Worldwide effective income tax rate (as a percent) 12.60% 19.30%
Effective income tax rate reconciliation, tax settlement, percent   22.00%
Unrecognized tax benefits $ 2,600  
Reduction in effective income tax rate 5.10% 0.40%
Talc | General Corporate    
Income Tax Contingency    
Reversal of fee expense   $ 7,000
Litigation expense $ 300  
v3.26.1
Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Retirement Plans    
Components of net periodic benefit cost    
Service cost $ 236 $ 214
Interest cost 360 351
Expected return on plan assets (639) (587)
Amortization of prior service cost/‍(credit) (46) (46)
Recognized actuarial (gains)/losses 69 83
Net periodic benefit cost/(credit) (20) 15
Other Benefit Plans    
Components of net periodic benefit cost    
Service cost 80 72
Interest cost 52 54
Expected return on plan assets (2) (2)
Amortization of prior service cost/‍(credit) 0 0
Recognized actuarial (gains)/losses 26 16
Net periodic benefit cost/(credit) $ 156 $ 140
v3.26.1
Pensions and other benefit plans (Details)
$ in Millions
 3 Months Ended
Mar. 29, 2026
USD ($)
U.S.  
Defined Benefit Plan Disclosure [Line Items]  
Contribution to pension plans $ 35
Foreign Plan  
Defined Benefit Plan Disclosure [Line Items]  
Contribution to pension plans $ 5
v3.26.1
Accumulated other comprehensive income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance $ 81,544 $ 71,490
Ending balance 81,186 78,109
Change from continuing operations 99 1
Foreign Currency Translation    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (13,947)  
Net change 334  
Ending balance (13,613)  
Gain/ (Loss) On Securities    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance 0  
Net change 0  
Ending balance 0  
Employee Benefit Plans    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (693)  
Net change 39  
Ending balance (654)  
Gain/ (Loss) On Derivatives & Hedges    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (290)  
Net change (274)  
Ending balance (564)  
Total Accumulated Other Comprehensive Income/(Loss)    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (14,930) (11,741)
Ending balance (14,831) (11,740)
Change from continuing operations $ 99 $ 1
v3.26.1
Earnings per share (Details) - $ / shares
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Reconciliation of basic net earnings per share to diluted net earnings per share    
Total net earnings per share - basic (in dollars per share) $ 2.17 $ 4.57
Average shares outstanding — basic 2,408,700,000 2,407,200,000
Potential shares exercisable under stock option plans 100,600,000 69,000,000.0
Less: shares which could be repurchased under treasury stock method (64,100,000) (52,400,000)
Average shares outstanding — diluted 2,445,200,000 2,423,800,000
Total net earnings per share - diluted (in dollars per share) $ 2.14 $ 4.54
Antidilutive securities excluded from computation of earnings per share, amount 3,500,000 60,900,000
v3.26.1
Segments of business and geographic areas - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 29, 2026
USD ($)
segment
Mar. 30, 2025
USD ($)
Oct. 14, 2025
Segment Reporting Information [Line Items]      
Number of operating segments | segment 2    
Number of reportable segments | segment 2    
Sales to customers (Note 9) | $ $ 24,062 $ 21,893  
Innovative Medicine      
Segment Reporting Information [Line Items]      
Sales to customers (Note 9) | $ $ 15,426 $ 13,873  
Innovative Medicine | Change in Accounting Method Accounted for as Change in Estimate      
Segment Reporting Information [Line Items]      
Adjustments To Revenue Recognized, Percent 4.70% 4.60%  
Minimum | Orthopaedics Business      
Segment Reporting Information [Line Items]      
Disposal group, estimated term to complete     18 months
Maximum | Orthopaedics Business      
Segment Reporting Information [Line Items]      
Disposal group, estimated term to complete     24 months
v3.26.1
Segments of business and geographic areas - Sales By Segment Of Business (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Sales by segment of business    
Sales to customers $ 24,062 $ 21,893
Percent Change (as a percent) 9.90%  
U.S.    
Sales by segment of business    
Sales to customers $ 13,330 12,305
Percent Change (as a percent) 8.30%  
International    
Sales by segment of business    
Sales to customers $ 10,732 9,588
Percent Change (as a percent) 11.90%  
Innovative Medicine    
Sales by segment of business    
Sales to customers $ 15,426 13,873
Percent Change (as a percent) 11.20%  
Innovative Medicine | U.S.    
Sales by segment of business    
Sales to customers $ 8,871 8,092
Percent Change (as a percent) 9.60%  
Innovative Medicine | International    
Sales by segment of business    
Sales to customers $ 6,555 5,781
Percent Change (as a percent) 13.40%  
Innovative Medicine | Oncology    
Sales by segment of business    
Sales to customers $ 6,973 5,678
Percent Change (as a percent) 22.80%  
Innovative Medicine | Oncology | U.S.    
Sales by segment of business    
Sales to customers $ 3,615 3,013
Percent Change (as a percent) 20.00%  
Innovative Medicine | Oncology | International    
Sales by segment of business    
Sales to customers $ 3,358 2,664
Percent Change (as a percent) 26.00%  
Innovative Medicine | Oncology | DARZALEX    
Sales by segment of business    
Sales to customers $ 3,964 3,237
Percent Change (as a percent) 22.50%  
Innovative Medicine | Oncology | DARZALEX | U.S.    
Sales by segment of business    
Sales to customers $ 2,208 1,829
Percent Change (as a percent) 20.70%  
Innovative Medicine | Oncology | DARZALEX | International    
Sales by segment of business    
Sales to customers $ 1,756 1,409
Percent Change (as a percent) 24.70%  
Innovative Medicine | Oncology | CARVYKTI    
Sales by segment of business    
Sales to customers $ 597 369
Percent Change (as a percent) 62.10%  
Innovative Medicine | Oncology | CARVYKTI | U.S.    
Sales by segment of business    
Sales to customers $ 433 318
Percent Change (as a percent) 36.20%  
Innovative Medicine | Oncology | CARVYKTI | International    
Sales by segment of business    
Sales to customers $ 164 51
Innovative Medicine | Oncology | Tecvayli    
Sales by segment of business    
Sales to customers $ 202 151
Percent Change (as a percent) 33.50%  
Innovative Medicine | Oncology | Tecvayli | U.S.    
Sales by segment of business    
Sales to customers $ 127 105
Percent Change (as a percent) 20.60%  
Innovative Medicine | Oncology | Tecvayli | International    
Sales by segment of business    
Sales to customers $ 74 46
Percent Change (as a percent) 63.10%  
Innovative Medicine | Oncology | TALVEY    
Sales by segment of business    
Sales to customers $ 152 86
Percent Change (as a percent) 76.70%  
Innovative Medicine | Oncology | TALVEY | U.S.    
Sales by segment of business    
Sales to customers $ 101 68
Percent Change (as a percent) 48.50%  
Innovative Medicine | Oncology | TALVEY | International    
Sales by segment of business    
Sales to customers $ 51 18
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE    
Sales by segment of business    
Sales to customers $ 257 141
Percent Change (as a percent) 82.70%  
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | U.S.    
Sales by segment of business    
Sales to customers $ 175 113
Percent Change (as a percent) 55.10%  
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | International    
Sales by segment of business    
Sales to customers $ 82 28
Innovative Medicine | Oncology | ERLEADA    
Sales by segment of business    
Sales to customers $ 949 771
Percent Change (as a percent) 23.10%  
Innovative Medicine | Oncology | ERLEADA | U.S.    
Sales by segment of business    
Sales to customers $ 342 292
Percent Change (as a percent) 17.30%  
Innovative Medicine | Oncology | ERLEADA | International    
Sales by segment of business    
Sales to customers $ 607 479
Percent Change (as a percent) 26.70%  
Innovative Medicine | Oncology | IMBRUVICA    
Sales by segment of business    
Sales to customers $ 660 709
Percent Change (as a percent) (6.90%)  
Innovative Medicine | Oncology | IMBRUVICA | U.S.    
Sales by segment of business    
Sales to customers $ 143 235
Percent Change (as a percent) (39.10%)  
Innovative Medicine | Oncology | IMBRUVICA | International    
Sales by segment of business    
Sales to customers $ 517 474
Percent Change (as a percent) 9.10%  
Innovative Medicine | Oncology | Other Oncology    
Sales by segment of business    
Sales to customers $ 192 214
Percent Change (as a percent) (10.60%)  
Innovative Medicine | Oncology | Other Oncology | U.S.    
Sales by segment of business    
Sales to customers $ 85 54
Percent Change (as a percent) 58.80%  
Innovative Medicine | Oncology | Other Oncology | International    
Sales by segment of business    
Sales to customers $ 106 160
Percent Change (as a percent) (33.90%)  
Innovative Medicine | Immunology    
Sales by segment of business    
Sales to customers $ 3,380 3,707
Percent Change (as a percent) (8.80%)  
Innovative Medicine | Immunology | U.S.    
Sales by segment of business    
Sales to customers $ 1,855 2,196
Percent Change (as a percent) (15.50%)  
Innovative Medicine | Immunology | International    
Sales by segment of business    
Sales to customers $ 1,524 1,510
Percent Change (as a percent) 0.90%  
Innovative Medicine | Immunology | Tremfya    
Sales by segment of business    
Sales to customers $ 1,608 956
Percent Change (as a percent) 68.30%  
Innovative Medicine | Immunology | Tremfya | U.S.    
Sales by segment of business    
Sales to customers $ 1,042 599
Percent Change (as a percent) 73.90%  
Innovative Medicine | Immunology | Tremfya | International    
Sales by segment of business    
Sales to customers $ 566 356
Percent Change (as a percent) 58.90%  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA    
Sales by segment of business    
Sales to customers $ 647 659
Percent Change (as a percent) (1.70%)  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S.    
Sales by segment of business    
Sales to customers $ 269 292
Percent Change (as a percent) (7.80%)  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International    
Sales by segment of business    
Sales to customers $ 378 366
Percent Change (as a percent) 3.00%  
Innovative Medicine | Immunology | Remicade    
Sales by segment of business    
Sales to customers $ 422 467
Percent Change (as a percent) (9.50%)  
Innovative Medicine | Immunology | Remicade | U.S.    
Sales by segment of business    
Sales to customers $ 269 314
Percent Change (as a percent) (14.40%)  
Innovative Medicine | Immunology | Remicade | International    
Sales by segment of business    
Sales to customers $ 18 10
Percent Change (as a percent) 78.60%  
Innovative Medicine | Immunology | Remicade | International    
Sales by segment of business    
Sales to customers $ 136 143
Percent Change (as a percent) (4.80%)  
Innovative Medicine | Immunology | STELARA    
Sales by segment of business    
Sales to customers $ 656 1,625
Percent Change (as a percent) (59.70%)  
Innovative Medicine | Immunology | STELARA | U.S.    
Sales by segment of business    
Sales to customers $ 220 981
Percent Change (as a percent) (77.60%)  
Innovative Medicine | Immunology | STELARA | International    
Sales by segment of business    
Sales to customers $ 435 644
Percent Change (as a percent) (32.40%)  
Innovative Medicine | Immunology | OTHER IMMUNOLOGY    
Sales by segment of business    
Sales to customers $ 46 1
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S.    
Sales by segment of business    
Sales to customers 38 1
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International    
Sales by segment of business    
Sales to customers 9 0
Innovative Medicine | Infectious Diseases    
Sales by segment of business    
Sales to customers $ 889 802
Percent Change (as a percent) 10.80%  
Innovative Medicine | Infectious Diseases | U.S.    
Sales by segment of business    
Sales to customers $ 342 315
Percent Change (as a percent) 8.60%  
Innovative Medicine | Infectious Diseases | International    
Sales by segment of business    
Sales to customers $ 547 487
Percent Change (as a percent) 12.20%  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine    
Sales by segment of business    
Sales to customers $ 409 358
Percent Change (as a percent) 14.10%  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | U.S.    
Sales by segment of business    
Sales to customers $ 7 8
Percent Change (as a percent) (13.10%)  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | International    
Sales by segment of business    
Sales to customers $ 402 350
Percent Change (as a percent) 14.80%  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA    
Sales by segment of business    
Sales to customers $ 443 403
Percent Change (as a percent) 10.00%  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | U.S.    
Sales by segment of business    
Sales to customers $ 334 305
Percent Change (as a percent) 9.50%  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | International    
Sales by segment of business    
Sales to customers $ 109 98
Percent Change (as a percent) 11.20%  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES    
Sales by segment of business    
Sales to customers $ 37 41
Percent Change (as a percent) (10.40%)  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.    
Sales by segment of business    
Sales to customers $ 1 2
Percent Change (as a percent) (56.90%)  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International    
Sales by segment of business    
Sales to customers $ 36 39
Percent Change (as a percent) (8.30%)  
Innovative Medicine | Neuroscience    
Sales by segment of business    
Sales to customers $ 2,175 1,647
Percent Change (as a percent) 32.00%  
Innovative Medicine | Neuroscience | U.S.    
Sales by segment of business    
Sales to customers $ 1,494 968
Percent Change (as a percent) 54.30%  
Innovative Medicine | Neuroscience | International    
Sales by segment of business    
Sales to customers $ 681 679
Percent Change (as a percent) 0.30%  
Innovative Medicine | Neuroscience | SPRAVATO    
Sales by segment of business    
Sales to customers $ 468 320
Percent Change (as a percent) 46.40%  
Innovative Medicine | Neuroscience | SPRAVATO | U.S.    
Sales by segment of business    
Sales to customers $ 406 276
Percent Change (as a percent) 47.00%  
Innovative Medicine | Neuroscience | SPRAVATO | International    
Sales by segment of business    
Sales to customers $ 61 43
Percent Change (as a percent) 42.40%  
Innovative Medicine | Neuroscience | CAPLYTA    
Sales by segment of business    
Sales to customers $ 270 0
Innovative Medicine | Neuroscience | CAPLYTA | U.S.    
Sales by segment of business    
Sales to customers 270 0
Innovative Medicine | Neuroscience | CAPLYTA | International    
Sales by segment of business    
Sales to customers $ 0 0
Percent Change (as a percent) 0.00%  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA    
Sales by segment of business    
Sales to customers $ 1,038 903
Percent Change (as a percent) 15.00%  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.    
Sales by segment of business    
Sales to customers $ 758 625
Percent Change (as a percent) 21.20%  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International    
Sales by segment of business    
Sales to customers $ 280 277
Percent Change (as a percent) 1.10%  
Innovative Medicine | Neuroscience | CONCERTA/Methylphenidate    
Sales by segment of business    
Sales to customers $ 136 148
Percent Change (as a percent) (8.00%)  
Innovative Medicine | Neuroscience | CONCERTA/Methylphenidate | U.S.    
Sales by segment of business    
Sales to customers $ 22 38
Percent Change (as a percent) (43.40%)  
Innovative Medicine | Neuroscience | CONCERTA/Methylphenidate | International    
Sales by segment of business    
Sales to customers $ 115 110
Percent Change (as a percent) 4.30%  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE    
Sales by segment of business    
Sales to customers $ 262 277
Percent Change (as a percent) (5.40%)  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S.    
Sales by segment of business    
Sales to customers $ 38 28
Percent Change (as a percent) 32.60%  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International    
Sales by segment of business    
Sales to customers $ 224 248
Percent Change (as a percent) (9.70%)  
Innovative Medicine | Pulmonary Hypertension    
Sales by segment of business    
Sales to customers $ 1,135 1,025
Percent Change (as a percent) 10.70%  
Innovative Medicine | Pulmonary Hypertension | U.S.    
Sales by segment of business    
Sales to customers $ 831 744
Percent Change (as a percent) 11.70%  
Innovative Medicine | Pulmonary Hypertension | International    
Sales by segment of business    
Sales to customers $ 304 281
Percent Change (as a percent) 8.20%  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI    
Sales by segment of business    
Sales to customers $ 483 451
Percent Change (as a percent) 7.10%  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S.    
Sales by segment of business    
Sales to customers $ 385 365
Percent Change (as a percent) 5.40%  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International    
Sales by segment of business    
Sales to customers $ 98 86
Percent Change (as a percent) 14.30%  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI    
Sales by segment of business    
Sales to customers $ 606 522
Percent Change (as a percent) 16.10%  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | U.S.    
Sales by segment of business    
Sales to customers $ 433 363
Percent Change (as a percent) 19.30%  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | International    
Sales by segment of business    
Sales to customers $ 172 159
Percent Change (as a percent) 8.70%  
Innovative Medicine | Pulmonary Hypertension | Other    
Sales by segment of business    
Sales to customers $ 46 52
Percent Change (as a percent) (12.10%)  
Innovative Medicine | Pulmonary Hypertension | Other | U.S.    
Sales by segment of business    
Sales to customers $ 12 15
Percent Change (as a percent) (21.10%)  
Innovative Medicine | Pulmonary Hypertension | Other | International    
Sales by segment of business    
Sales to customers $ 34 37
Percent Change (as a percent) (8.30%)  
Innovative Medicine | Cardiovascular / Metabolism / Other    
Sales by segment of business    
Sales to customers $ 876 1,013
Percent Change (as a percent) (13.60%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S.    
Sales by segment of business    
Sales to customers $ 734 855
Percent Change (as a percent) (14.20%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | International    
Sales by segment of business    
Sales to customers $ 142 158
Percent Change (as a percent) (10.40%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other    
Sales by segment of business    
Sales to customers $ 233 323
Percent Change (as a percent) (27.80%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S.    
Sales by segment of business    
Sales to customers $ 91 165
Percent Change (as a percent) (44.50%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International    
Sales by segment of business    
Sales to customers $ 142 158
Percent Change (as a percent) (10.40%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO    
Sales by segment of business    
Sales to customers $ 642 690
Percent Change (as a percent) (7.00%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S.    
Sales by segment of business    
Sales to customers $ 642 690
Percent Change (as a percent) (7.00%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International    
Sales by segment of business    
Sales to customers $ 0 0
Percent Change (as a percent) 0.00%  
Innovative Medicine | Total PH, ID, CVM | Other    
Sales by segment of business    
Sales to customers $ 2,899 2,840
Percent Change (as a percent) 2.10%  
Innovative Medicine | Total PH, ID, CVM | Other | U.S.    
Sales by segment of business    
Sales to customers $ 1,907 1,914
Percent Change (as a percent) (0.40%)  
Innovative Medicine | Total PH, ID, CVM | Other | International    
Sales by segment of business    
Sales to customers $ 993 926
Percent Change (as a percent) 7.10%  
MEDTECH    
Sales by segment of business    
Sales to customers $ 8,636 8,020
Percent Change (as a percent) 7.70%  
MEDTECH | U.S.    
Sales by segment of business    
Sales to customers $ 4,459 4,213
Percent Change (as a percent) 5.90%  
MEDTECH | International    
Sales by segment of business    
Sales to customers $ 4,177 3,807
Percent Change (as a percent) 9.70%  
MEDTECH | Cardiovascular    
Sales by segment of business    
Sales to customers $ 2,377 2,103
Percent Change (as a percent) 13.00%  
MEDTECH | Cardiovascular | U.S.    
Sales by segment of business    
Sales to customers $ 1,399 1,261
Percent Change (as a percent) 10.90%  
MEDTECH | Cardiovascular | International    
Sales by segment of business    
Sales to customers $ 978 842
Percent Change (as a percent) 16.10%  
MEDTECH | ELECTROPHYSIOLOGY    
Sales by segment of business    
Sales to customers $ 1,489 1,323
Percent Change (as a percent) 12.60%  
MEDTECH | ELECTROPHYSIOLOGY | U.S.    
Sales by segment of business    
Sales to customers $ 736 684
Percent Change (as a percent) 7.60%  
MEDTECH | ELECTROPHYSIOLOGY | International    
Sales by segment of business    
Sales to customers $ 753 638
Percent Change (as a percent) 18.00%  
MEDTECH | ABIOMED    
Sales by segment of business    
Sales to customers $ 488 420
Percent Change (as a percent) 16.30%  
MEDTECH | ABIOMED | U.S.    
Sales by segment of business    
Sales to customers $ 389 339
Percent Change (as a percent) 14.50%  
MEDTECH | ABIOMED | International    
Sales by segment of business    
Sales to customers $ 100 81
Percent Change (as a percent) 23.50%  
MEDTECH | Shockwave    
Sales by segment of business    
Sales to customers $ 305 258
Percent Change (as a percent) 18.50%  
MEDTECH | Shockwave | U.S.    
Sales by segment of business    
Sales to customers $ 242 206
Percent Change (as a percent) 17.80%  
MEDTECH | Shockwave | International    
Sales by segment of business    
Sales to customers $ 63 52
Percent Change (as a percent) 21.30%  
MEDTECH | Other Cardiovascular    
Sales by segment of business    
Sales to customers $ 94 103
Percent Change (as a percent) (9.10%)  
MEDTECH | Other Cardiovascular | U.S.    
Sales by segment of business    
Sales to customers $ 32 32
Percent Change (as a percent) 0.70%  
MEDTECH | Other Cardiovascular | International    
Sales by segment of business    
Sales to customers $ 62 72
Percent Change (as a percent) (13.40%)  
MEDTECH | Orthopaedics    
Sales by segment of business    
Sales to customers $ 2,383 2,241
Percent Change (as a percent) 6.30%  
MEDTECH | Orthopaedics | U.S.    
Sales by segment of business    
Sales to customers $ 1,435 1,384
Percent Change (as a percent) 3.70%  
MEDTECH | Orthopaedics | International    
Sales by segment of business    
Sales to customers $ 948 857
Percent Change (as a percent) 10.60%  
MEDTECH | Orthopaedics | HIPS    
Sales by segment of business    
Sales to customers $ 436 409
Percent Change (as a percent) 6.50%  
MEDTECH | Orthopaedics | HIPS | U.S.    
Sales by segment of business    
Sales to customers $ 277 263
Percent Change (as a percent) 5.20%  
MEDTECH | Orthopaedics | HIPS | International    
Sales by segment of business    
Sales to customers $ 159 146
Percent Change (as a percent) 8.90%  
MEDTECH | Orthopaedics | KNEES    
Sales by segment of business    
Sales to customers $ 420 389
Percent Change (as a percent) 7.90%  
MEDTECH | Orthopaedics | KNEES | U.S.    
Sales by segment of business    
Sales to customers $ 239 231
Percent Change (as a percent) 3.30%  
MEDTECH | Orthopaedics | KNEES | International    
Sales by segment of business    
Sales to customers $ 181 158
Percent Change (as a percent) 14.60%  
MEDTECH | Orthopaedics | TRAUMA    
Sales by segment of business    
Sales to customers $ 833 772
Percent Change (as a percent) 8.00%  
MEDTECH | Orthopaedics | TRAUMA | U.S.    
Sales by segment of business    
Sales to customers $ 532 502
Percent Change (as a percent) 6.10%  
MEDTECH | Orthopaedics | TRAUMA | International    
Sales by segment of business    
Sales to customers $ 301 270
Percent Change (as a percent) 11.40%  
MEDTECH | Orthopaedics | SPINE & OTHER    
Sales by segment of business    
Sales to customers $ 694 671
Percent Change (as a percent) 3.50%  
MEDTECH | Orthopaedics | SPINE & OTHER | U.S.    
Sales by segment of business    
Sales to customers $ 387 388
Percent Change (as a percent) (0.10%)  
MEDTECH | Orthopaedics | SPINE & OTHER | International    
Sales by segment of business    
Sales to customers $ 307 283
Percent Change (as a percent) 8.40%  
MEDTECH | Surgery    
Sales by segment of business    
Sales to customers $ 2,511 2,396
Percent Change (as a percent) 4.80%  
MEDTECH | Surgery | U.S.    
Sales by segment of business    
Sales to customers $ 1,046 1,002
Percent Change (as a percent) 4.40%  
MEDTECH | Surgery | International    
Sales by segment of business    
Sales to customers $ 1,465 1,394
Percent Change (as a percent) 5.10%  
MEDTECH | Surgery | ADVANCED    
Sales by segment of business    
Sales to customers $ 1,123 1,073
Percent Change (as a percent) 4.60%  
MEDTECH | Surgery | ADVANCED | U.S.    
Sales by segment of business    
Sales to customers $ 477 457
Percent Change (as a percent) 4.20%  
MEDTECH | Surgery | ADVANCED | International    
Sales by segment of business    
Sales to customers $ 646 616
Percent Change (as a percent) 4.90%  
MEDTECH | Surgery | GENERAL    
Sales by segment of business    
Sales to customers $ 1,388 1,323
Percent Change (as a percent) 4.90%  
MEDTECH | Surgery | GENERAL | U.S.    
Sales by segment of business    
Sales to customers $ 569 544
Percent Change (as a percent) 4.50%  
MEDTECH | Surgery | GENERAL | International    
Sales by segment of business    
Sales to customers $ 819 778
Percent Change (as a percent) 5.20%  
MEDTECH | Vision    
Sales by segment of business    
Sales to customers $ 1,365 1,279
Percent Change (as a percent) 6.70%  
MEDTECH | Vision | U.S.    
Sales by segment of business    
Sales to customers $ 579 566
Percent Change (as a percent) 2.40%  
MEDTECH | Vision | International    
Sales by segment of business    
Sales to customers $ 785 713
Percent Change (as a percent) 10.10%  
MEDTECH | Vision | CONTACT LENSES / OTHER    
Sales by segment of business    
Sales to customers $ 969 919
Percent Change (as a percent) 5.50%  
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S.    
Sales by segment of business    
Sales to customers $ 468 452
Percent Change (as a percent) 3.70%  
MEDTECH | Vision | CONTACT LENSES / OTHER | International    
Sales by segment of business    
Sales to customers $ 501 467
Percent Change (as a percent) 7.20%  
MEDTECH | Vision | SURGICAL    
Sales by segment of business    
Sales to customers $ 396 361
Percent Change (as a percent) 9.70%  
MEDTECH | Vision | SURGICAL | U.S.    
Sales by segment of business    
Sales to customers $ 111 114
Percent Change (as a percent) (2.90%)  
MEDTECH | Vision | SURGICAL | International    
Sales by segment of business    
Sales to customers $ 285 $ 246
Percent Change (as a percent) 15.60%  
v3.26.1
Segments of business and geographic areas - Operating Profit by Segment of Business (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Segment Reporting Information [Line Items]    
Restructuring (Note 12) $ 32 $ 17
Sales to customers (Note 9) 24,062 21,893
Cost of products sold 8,106 7,357
Selling, marketing and administrative expenses 6,034 5,112
Research and development expense 3,527 3,225
Other (income) expense, net (294) 7,321
Earnings before provision for taxes on income 5,990 13,631
Less: Expense not allocated to segments 566 (7,000)
Innovative Medicine    
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) 15,426 13,873
MedTech    
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) 8,636 8,020
Acquisition related costs   100
MedTech | Separation Related Costs    
Segment Reporting Information [Line Items]    
Restructuring (Note 12) 100  
General Corporate | Talc    
Segment Reporting Information [Line Items]    
Litigation expense 300  
Reversal of fee expense   7,000
Operating Segments    
Segment Reporting Information [Line Items]    
Restructuring (Note 12) 62 55
Earnings before provision for taxes on income 6,556 6,631
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) 15,426 13,873
Cost of products sold 4,390 4,020
Selling, marketing and administrative expenses 2,918 2,261
Research and development expense 2,813 2,548
Other (income) expense, net (12) (166)
Earnings before provision for taxes on income 5,317 5,210
Amortization 800 600
Operating Segments | MedTech    
Segment Reporting Information [Line Items]    
Restructuring (Note 12) 7 55
Sales to customers (Note 9) 8,636 8,020
Cost of products sold 3,701 3,326
Selling, marketing and administrative expenses 2,906 2,656
Research and development expense 714 677
Other (income) expense, net 76 (60)
Earnings before provision for taxes on income 1,239 1,421
Amortization $ 500 $ 500
v3.26.1
Segments of business and geographic areas - Identifiable Assets (Details) - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 28, 2025
Segment Reporting Information [Line Items]    
Assets $ 200,894 $ 199,210
Segments Total    
Segment Reporting Information [Line Items]    
Assets 164,297 164,539
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Assets 78,118 78,057
Operating Segments | MEDTECH    
Segment Reporting Information [Line Items]    
Assets 86,179 86,482
Corporate, Non-Segment | General Corporate    
Segment Reporting Information [Line Items]    
Assets $ 36,597 $ 34,671
v3.26.1
Segments of business and geographic areas - Additions to Property, Plan & Equipment and Depreciation and Amortization (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment $ 1,049 $ 795
Depreciation and Amortization 2,004 1,772
Segments Total    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 1,017 756
Depreciation and Amortization 1,939 1,720
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 508 276
Depreciation and Amortization 1,036 884
Operating Segments | MEDTECH    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 509 480
Depreciation and Amortization 903 836
Corporate, Non-Segment | General Corporate    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 32 39
Depreciation and Amortization $ 65 $ 52
v3.26.1
Segments of business and geographic areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Sales by geographic area    
Sales $ 24,062 $ 21,893
Percent Change 9.90%  
United States    
Sales by geographic area    
Sales $ 13,330 12,305
Percent Change 8.30%  
Europe    
Sales by geographic area    
Sales $ 5,848 5,110
Percent Change 14.50%  
Western Hemisphere, excluding U.S.    
Sales by geographic area    
Sales $ 1,293 1,167
Percent Change 10.80%  
Asia-Pacific, Africa    
Sales by geographic area    
Sales $ 3,591 $ 3,311
Percent Change 8.50%  
v3.26.1
Acquisitions, divestitures and other arrangements - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended 24 Months Ended
Dec. 26, 2025
Apr. 02, 2025
Dec. 28, 2025
Jan. 02, 2028
Mar. 29, 2026
Business Combination [Line Items]          
Payments to acquire businesses     $ 17,500    
Goodwill (Note 3)     $ 48,772   $ 48,558
Royalty Pharma plc.          
Business Combination [Line Items]          
Milestone payments receivable         $ 500
Scenario, Forecast          
Business Combination [Line Items]          
Other commitment, maximum funds to receive       $ 500  
Halda Therapeutics          
Business Combination [Line Items]          
Payments to acquire businesses $ 3,050        
Acquisition related costs 200        
Assets acquired including goodwill 3,400        
Goodwill (Note 3) 600        
Liabilities assumed 600        
Halda Therapeutics | In-process research and development          
Business Combination [Line Items]          
Asset acquired, identifiable intangible asset, indefinite-lived $ 2,800        
Intra-Cellular Therapies, Inc.          
Business Combination [Line Items]          
Acquisition related costs   $ 400      
Goodwill (Note 3)   2,900      
Liabilities assumed   $ 3,000      
Share price (in dollars per share)   $ 132.00      
Consideration transferred   $ 14,500      
Integration-related cost, expense   100      
Assets acquired   17,500      
Amortizable intangibles asset   5,200      
Business combination, other asset   1,100      
Intra-Cellular Therapies, Inc. | In-process research and development          
Business Combination [Line Items]          
Asset acquired, identifiable intangible asset, indefinite-lived   $ 8,300      
v3.26.1
Legal proceedings (Details)
$ in Billions
 1 Months Ended 3 Months Ended
Jan. 31, 2026
USD ($)
Mar. 29, 2026
USD ($)
plaintiff
Mar. 30, 2025
USD ($)
Legal Proceeding (Textuals)      
Number of plaintiffs | plaintiff   75,000  
Payments for legal settlements $ 0.8    
Talc      
Legal Proceeding (Textuals)      
Loss contingency accrual   $ 3.4  
Loss contingency accrual, payment percentage   33.00%  
Talc | General Corporate      
Legal Proceeding (Textuals)      
Reversal of fee expense     $ 7.0
v3.26.1
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 32 $ 17
MedTech Surgery Franchise    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges recorded to date 300  
MedTech Surgery Franchise | Minimum    
Restructuring Cost and Reserve [Line Items]    
Restructuring estimated cost 900  
MedTech Surgery Franchise | Maximum    
Restructuring Cost and Reserve [Line Items]    
Restructuring estimated cost 1,000  
Orthopaedics Restructuring Plan    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges recorded to date $ 800  
v3.26.1
Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 32 $ 17
Operating Segments    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 62 55
MEDTECH | Operating Segments    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 7 55
MEDTECH | Restructuring Charges    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   17
MEDTECH | Costs of Goods and Services Sold    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   8
MEDTECH | Other (income) expense    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   30
MedTech Surgery Franchise | Operating Segments    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 55 $ 0
MedTech Surgery Franchise | Restructuring Charges    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 30  
MedTech Surgery Franchise | Costs of Goods and Services Sold    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 20  
MedTech Surgery Franchise | Other (income) expense    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 5